Lynparza

1

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS



2

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 50 mg hard capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard capsule contains 50 mg of olaparib.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Hard capsule.

White, opaque, size 0 hard capsule, marked with “OLAPARIB 50 mg” and the AstraZeneca logo in 
black ink.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with 
platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial 
ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial 
response) to platinum-based chemotherapy. 

4.2 Posology and method of administration

Treatment with Lynparza should be initiated and supervised by a physician experienced in the use of 
anticancer medicinal products.

Patients must have confirmation of a deleterious or suspected deleterious breast cancer susceptibility 
gene (BRCA) mutation (either germline or tumour) before Lynparza treatment is initiated. BRCA
mutation status should be determined by an experienced laboratory using a validated test method (see 
section 5.1).

Genetic counselling for patients with BRCA1/2 mutations should be performed according to local 
regulations.

Posology

The recommended dose of Lynparza is 400 mg (eight capsules) taken twice daily, equivalent to a total 
daily dose of 800 mg. 

Patients should start treatment with Lynparza no later than 8 weeks after completion of their final dose 
of the platinum-containing regimen.

It is recommended that treatment be continued until progression of the underlying disease or 
unacceptable toxicity. There are no data on retreatment with Lynparza following subsequent relapse 
(see section 5.1). 



3

Important differences in posology between Lynparza capsules and tablets
Lynparza capsules (50 mg) should not be substituted for Lynparza tablets (100 mg and 150 mg) on a 
milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. 
Therefore, the specific dose recommendations for each formulation should be followed.

Missing dose
If a patient misses a dose of Lynparza, they should take their next normal dose at its scheduled time.

Dose adjustments for adverse reactions
Treatment may be interrupted to manage adverse reactions such as nausea, vomiting, diarrhoea and 
anaemia and dose reduction can be considered (see section 4.8).

The recommended dose reduction is to 200 mg twice daily (equivalent to a total daily dose of 
400 mg).

If a further dose reduction is required, then reduction to 100 mg twice daily (equivalent to a total daily 
dose of 200 mg) is recommended.

Dose adjustments for co-administration with CYP3A inhibitors
Concomitant use of strong or moderate CYP3A inhibitors is not recommended and alternative agents 
should be considered. If a strong CYP3A inhibitor must be co-administered, the recommended 
Lynparza dose reduction is to 150 mg taken twice daily (equivalent to a total daily dose of 300 mg). If 
a moderate CYP3A inhibitor must be co-administered, the recommended Lynparza dose reduction is 
to 200 mg taken twice daily (equivalent to a total daily dose of 400 mg) (see sections 4.4 and 4.5).

Special populations

Elderly 
No adjustment in starting dose is required for elderly patients. There are limited clinical data in 
patients aged 75 years and over. 

Renal impairment 
For patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min) the recommended 
dose of Lynparza is 300 mg twice daily (equivalent to a total daily dose of 600 mg) (see section 5.2). 

Lynparza can be administered in patients with mild renal impairment (creatinine clearance 51 to 
80 ml/min) with no dose adjustment.

Lynparza is not recommended for use in patients with severe renal impairment or end-stage renal 
disease (creatinine clearance ≤ 30 ml/min) as safety and pharmacokinetics have not been studied in 
these patients. Lynparza may only be used in patients with severe renal impairment if the benefit 
outweighs the potential risk, and the patient should be carefully monitored for renal function and 
adverse events. 

Hepatic impairment 
Lynparza can be administered to patients with mild or moderate hepatic impairment (Child-Pugh 
classification A or B) with no dose adjustment (see section 5.2). Lynparza is not recommended for use 
in patients with severe hepatic impairment (Child-Pugh classification C), as safety and 
pharmacokinetics have not been studied in these patients.

Non-Caucasian patients
There are limited clinical data available in non-Caucasian patients. However, no dose adjustment is 
required on the basis of ethnicity (see section 5.2). 



4

Paediatric population
The safety and efficacy of Lynparza in children and adolescents has not been established. 
No data are available.

Method of administration 

Lynparza is for oral use. 

Due to the effect of food on olaparib absorption, patients should take Lynparza at least one hour after 
food, and refrain from eating preferably for up to 2 hours afterwards. 

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Breast-feeding during treatment and 1 month after the last dose (see section 4.6).

4.4 Special warnings and precautions for use

Haematological toxicity 
Haematological toxicity has been reported in patients treated with Lynparza, including clinical 
diagnoses and/or laboratory findings of generally mild or moderate (CTCAE grade 1 or 2) anaemia, 
neutropenia, thrombocytopenia and lymphopenia. Patients should not start treatment with Lynparza 
until they have recovered from haematological toxicity caused by previous anticancer therapy 
(haemoglobin, platelet and neutrophil levels should be ≤CTCAE grade 1). Baseline testing, followed 
by monthly monitoring, of complete blood counts is recommended for the first 12 months of treatment 
and periodically after this time to monitor for clinically significant changes in any parameter during 
treatment (see section 4.8).

If a patient develops severe haematological toxicity or blood transfusion dependence, treatment with 
Lynparza should be interrupted and appropriate haematological testing should be initiated. If the blood
parameters remain clinically abnormal after 4 weeks of Lynparza dose interruption, bone marrow 
analysis and/or blood cytogenetic analysis are recommended. 

Myelodysplastic syndrome/Acute myeloid leukaemia 
The overall incidence of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) in patients 
treated in clinical trials with Lynparza monotherapy, including long-term survival follow-up, was 
<1.5% and the majority of events had a fatal outcome. The duration of therapy with olaparib in 
patients who developed MDS/AML varied from < 6 months to > 2 years. All patients had potential 
contributing factors for the development of MDS/AML; having received previous chemotherapy with 
platinum agents. Many had also received other DNA damaging agents and radiotherapy. The majority 
of reports were in germline breast cancer susceptibility gene 1 or 2 (gBRCA1/2) mutation carriers. The 
incidence of MDS/AML cases was similar among gBRCA1m and gBRCA2m patients (1.7% and 1.4%, 
respectively). Some of the patients had a history of previous cancer or of bone marrow dysplasia. If 
MDS and/or AML are confirmed while on treatment with Lynparza, it is recommended that Lynparza 
should be discontinued and the patient be treated appropriately. 

Pneumonitis 
Pneumonitis, including events with a fatal outcome, has been reported in <1.0% of patients treated 
with Lynparza in clinical studies. Reports of pneumonitis had no consistent clinical pattern and were 
confounded by a number of pre-disposing factors (cancer and/or metastases in lungs, underlying 
pulmonary disease, smoking history, and/or previous chemotherapy and radiotherapy). If patients 
present with new or worsening respiratory symptoms such as dyspnoea, cough and fever, or an 
abnormal chest radiologic finding is observed, Lynparza treatment should be interrupted and prompt 
investigation initiated. If pneumonitis is confirmed, Lynparza treatment should be discontinued and 
the patient treated appropriately.



5

Embryofoetal toxicity
Based on its mechanism of action (PARP inhibition), Lynparza could cause foetal harm when 
administered to a pregnant woman. Nonclinical studies in rats have shown that olaparib causes adverse 
effects on embryofoetal survival and induces major foetal malformations at exposures below those 
expected at the recommended human dose of 400 mg twice daily.

Pregnancy/contraception
Lynparza should not be used during pregnancy. Women of childbearing potential must use two forms 
of reliable contraception before starting Lynparza treatment, during therapy and for 1 month after 
receiving the last dose of Lynparza (see section 4.6). Two highly effective and complementary forms 
of contraception are recommended.

Interactions 
Lynparza co-administration with strong or moderate CYP3A inhibitors is not recommended (see 
section 4.5). If a strong or moderate CYP3A inhibitor must be co-administered, the dose of Lynparza 
should be reduced (see sections 4.2 and 4.5).

Lynparza co-administration with strong or moderate CYP3A inducers is not recommended. In the 
event that a patient already receiving Lynparza requires treatment with a strong or moderate CYP3A 
inducer, the prescriber should be aware that the efficacy of Lynparza may be substantially reduced 
(see section 4.5).

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions
Clinical studies of olaparib in combination with other anticancer medicinal products, including DNA 
damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. The 
recommended Lynparza monotherapy dose is not suitable for combination with myelosuppressive 
anticancer medicinal products. 

Combination of olaparib with vaccines or immunosuppressant agents has not been studied. Therefore, 
caution should be taken if these medicinal products are co-administered with Lynparza and patients 
should be closely monitored.

Pharmacokinetic interactions
Effect of other medicinal products on olaparib
CYP3A4/5 are the isozymes predominantly responsible for the metabolic clearance of olaparib. 

A clinical study to evaluate the impact of itraconazole, a known CYP3A inhibitor, has shown that co-
administration with olaparib increased mean olaparib Cmax by 42% (90% CI: 33-52%) and mean AUC 
by 170% (90% CI: 144-197%). Therefore, known strong (e.g. itraconazole, telithromycin, 
clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir) or 
moderate (e.g. erythromycin, diltiazem, fluconazole, verapamil) inhibitors of this isozyme are not 
recommended with Lynparza (see section 4.4). If strong or moderate CYP3A inhibitors must be co-
administered, the dose of Lynparza should be reduced. The recommended Lynparza dose reduction is
to 150 mg taken twice daily (equivalent to a total daily dose of 300 mg) with a strong CYP3A 
inhibitor or 200 mg taken twice daily (equivalent to a total daily dose of 400 mg) with a moderate 
CYP3A inhibitor (see sections 4.2 and 4.4). It is also not recommended to consume grapefruit juice 
while on Lynparza therapy as it is a CYP3A inhibitor.

A clinical study to evaluate the impact of rifampicin, a known CYP3A inducer, has shown that 
co-administration with olaparib decreased olaparib mean Cmax by 71% (90% CI: 76-67%) and mean 
AUC by 87% (90% CI: 89-84%). Therefore, known strong inducers of this isozyme (e.g. phenytoin, 
rifampicin, rifapentine, carbamazepine, nevirapine, phenobarbital and St John’s Wort) are not 
recommended with Lynparza, as it is possible that the efficacy of Lynparza could be substantially 
reduced. The magnitude of the effect of moderate to strong inducers (e.g. efavirenz, rifabutin) on 



6

olaparib exposure is not established, therefore the co-administration of Lynparza with these medicinal 
products is also not recommended (see section 4.4).

Effect of olaparib on other medicinal products
Olaparib inhibits CYP3A4 in vitro and is predicted to be a mild CYP3A inhibitor in vivo. Therefore, 
caution should be exercised when sensitive CYP3A substrates or substrates with a narrow therapeutic 
margin (e.g. simvastatin, cisapride, cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, 
tacrolimus and quetiapine) are combined with olaparib. Appropriate clinical monitoring is 
recommended for patients receiving CYP3A substrates with a narrow therapeutic margin 
concomitantly with olaparib.

Induction of CYP1A2, 2B6 and 3A4 has been shown in vitro with CYP2B6 being most likely to be 
induced to a clinically relevant extent. The potential for olaparib to induce CYP2C9, CYP2C19 and 
P-gp can also not be excluded. Therefore, olaparib upon co-administration may reduce the exposure to 
substrates of these metabolic enzymes and transport protein. The efficacy of some hormonal 
contraceptives may be reduced if co-administered with olaparib (see also sections 4.4 and 4.6).

In vitro, olaparib inhibits the efflux transporter P-gp (IC50 = 76µM), therefore it cannot be excluded 
that olaparib may cause clinically relevant drug interactions with substrates of P-gp (e.g. simvastatin, 
pravastatin, dabigatran, digoxin and colchicine). Appropriate clinical monitoring is recommended for 
patients receiving this type of medicinal product concomitantly.

In vitro, olaparib has been shown to be an inhibitor of BCRP, OATP1B1, OCT1, OCT2, OAT3, 
MATE1 and MATE2K. It cannot be excluded that olaparib may increase the exposure to substrates of 
BCRP (e.g. methotrexate, rosuvastatin), OATP1B1 (e.g. bosentan, glibenclamide, repaglinide, statins 
and valsartan), OCT1 (e.g. metformin), OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide and 
methotrexate), MATE1 (e.g. metformin) and MATE2K (e.g. metformin). In particular, caution should 
be exercised if olaparib is administered in combination with any statin. 

Combination with anastrozole, letrozole and tamoxifen
A clinical study has been performed to assess the combination of olaparib with anastrozole, letrozole 
or tamoxifen. No significant interaction was observed with anastrozole or letrozole whereas tamoxifen 
decreased exposure to olaparib by 27%. The clinical relevance of this effect is unknown. Olaparib 
does not affect the pharmacokinetics of tamoxifen.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/contraception in females
Women of childbearing potential should not become pregnant while on Lynparza and not be pregnant 
at the beginning of treatment. A pregnancy test should be performed on all women of childbearing 
potential prior to treatment and considered regularly throughout treatment. 

Women of childbearing potential must use two forms of reliable contraception before starting 
Lynparza therapy, during therapy and for 1 month after receiving the last dose of Lynparza, unless 
abstinence is the chosen method of contraception (see section 4.4). Two highly effective and 
complementary forms of contraception are recommended.

Since it cannot be excluded that olaparib may reduce exposure to substrates of CYP2C9 through 
enzyme induction, the efficacy of some hormonal contraceptives may be reduced if co-administered 
with olaparib. Therefore, an additional non-hormonal contraceptive method should be considered 
during treatment (see section 4.5). For women with hormone dependent cancer, two non-hormonal 
contraceptive methods should be considered.

Pregnancy
Studies in animals have shown reproductive toxicity including serious teratogenic effects and effects 
on embryofoetal survival in the rat at maternal systemic exposures lower than those in humans at 



7

therapeutic doses (see section 5.3). There are no data from the use of olaparib in pregnant women, 
however, based on the mode of action of olaparib, Lynparza should not be used during pregnancy and 
in women of childbearing potential not using reliable contraception during therapy and for 1 month 
after receiving the last dose of Lynparza. (See previous paragraph: “Women of childbearing 
potential/contraception in females” for further information about birth control and pregnancy testing.)

Breast-feeding
There are no animal studies on the excretion of olaparib in breast milk. It is unknown whether olaparib
or its metabolites are excreted in human milk. Lynparza is contraindicated during breast-feeding and 
for 1 month after receiving the last dose, given the pharmacologic property of the product (see 
section 4.3). 

Fertility
There are no clinical data on fertility. In animal studies, no effect on conception was observed but 
there are adverse effects on embryofoetal survival (see section 5.3). 

4.7 Effects on ability to drive and use machines

Lynparza has moderate influence on the ability to drive and use machines. Patients who take Lynparza 
may experience fatigue, asthenia or dizziness. Patients who experience these symptoms should 
observe caution when driving or using machines. 

4.8 Undesirable effects

Summary of the safety profile
Lynparza monotherapy has been associated with adverse reactions generally of mild or moderate 
severity (CTCAE grade 1 or 2) and generally not requiring treatment discontinuation. The most 
frequently observed adverse reactions across clinical trials in patients receiving Lynparza 
monotherapy (≥ 10%) were nausea, fatigue, vomiting, anaemia, diarrhoea, decreased appetite, 
headache, dysgeusia, neutropenia, cough, dyspnoea, dizziness, dyspepsia, leukopenia,
thrombocytopenia and upper abdominal pain.

The Grade ≥ 3 adverse reactions occurring in > 2% of patients were anaemia (16%), neutropenia (6%),
fatigue/asthenia (6%), leukopenia (3%), thrombocytopenia (3%) and vomiting (2%).

Adverse reactions that most commonly led to dose interruptions and/ or reductions were anaemia 
(14.9%), vomiting (7.2%), nausea (6.5%), fatigue/asthenia (6.2%) and neutropenia (6.2%). Adverse 
reactions that most commonly led to permanent discontinuation were anaemia (1.2%), nausea (0.7%), 
thrombocytopenia (0.6%) and vomiting (0.6%).

Tabulated list of adverse reactions
The safety profile is based on pooled data from 2095 patients with solid tumours treated with 
Lynparza monotherapy in clinical trials at the recommended dose.

The following adverse reactions have been identified in clinical trials with patients receiving Lynparza
monotherapy where patient exposure is known. Adverse drug reactions are listed by MedDRA System 
Organ Class (SOC) and then by MedDRA preferred term in Table 1. Within each SOC, preferred 
terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of 
occurrence of adverse reactions are defined as: very common (≥ 1/10); common ( 1/100 to < 1/10); 
uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000); not known 
(cannot be estimated from available data).



8

Table 1 Tabulated list of adverse reactions 

Adverse reactions

MedDRA 
System Organ 
Class

Frequency of All CTCAE grades Frequency of CTCAE grade 3 
and above 

Blood and 
lymphatic 
system disorders

Very common
Anaemiaa, Neutropeniaa, 
Thrombocytopeniaa, Leukopeniaa

Common
Lymphopeniaa

Very common
Anaemiaa

Common
Neutropeniaa, 
Thrombocytopeniaa, 
Leukopeniaa

Uncommon
Lymphopeniaa

Immune system 
disorders

Common
Rasha

Uncommon
Hypersensitivitya, Dermatitisa

-

Metabolism and 
nutrition 
disorders

Very common 
Decreased appetite

Uncommon
Decreased appetite

Nervous system 
disorders

Very common

Dizziness, Headache, Dysgeusia

Uncommon
Dizziness, Headache

Respiratory, 
thoracic and 
mediastinal 
disorders

Very common
Cougha, Dyspnoeaa

Common

Dyspnoeaa

Uncommon
Cougha

Gastrointestinal 
disorders

Very common
Vomiting, Diarrhoea, Nausea, Dyspepsia,
Upper abdominal pain

Common
Stomatitisa

Common
Vomiting, Diarrhoea, Nausea

Uncommon
Stomatitisa, Upper abdominal 
pain 

General 
disorders and 
administration 
site conditions

Very common
Fatigue (including asthenia) 

Common
Fatigue (including asthenia)

Investigations Common

Blood creatinine increased

Uncommon 
Mean cell volume increased

Uncommon 
Blood creatinine increased

a Anaemia includes preferred terms (PTs) of anaemia, anaemia macrocytic, erythropenia, haematocrit 
decreased, haemoglobin decreased, normochromic anaemia, normochromic normocytic anaemia, 
normocytic anaemia and red blood cell count decreased; Neutropenia includes PTs of agranulocytosis, 
febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, 
neutropenic infection, neutropenic sepsis and neutrophil count decreased; Thrombocytopenia includes 
PTs of platelet count decreased, platelet production decreased, plateletcrit decrease and 
thrombocytopenia; Leukopenia includes PTs of leukopenia and white blood cell count decreased; 
Lymphopenia includes PTs of B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia



9

and T-lymphocyte count decreased; Cough includes PTs of cough and productive cough; Rash includes 
PTs of exfoliative rash, generalised erythema, rash, rash erythematous, rash generalised, rash macular, 
rash maculo-papular, rash papular and rash pruritic; Hypersensitivity includes PTs of drug 
hypersensitivity and hypersensitivity; Dermatitis includes PTs of dermatitis, dermatitis allergic and 
dermatitis exfoliative. Dyspnoea includes PTs of dyspnoea and dyspnoea exertional; Stomatitis includes 
PTs of aphthous ulcer, mouth ulceration and stomatitis.

Description of selected adverse reactions

Haematological toxicity
Anaemia and other haematological toxicities were generally low grade (CTCAE grade 1 or 2), 
however, there were reports of CTCAE grade 3 and higher events. Anaemia was the most common 
CTCAE grade ≥3 adverse reaction reported in clinical studies. Median time to first onset of anaemia 
was approximately 4 weeks (approximately 7 weeks for CTCAE grade ≥ 3 events). Anaemia was 
managed with dose interruptions and dose reductions (see section 4.2), and where appropriate with 
blood transfusions. In Study 19, the incidence of anaemia was 22.8% (CTCAE grade ≥3 7.4%) and the 
incidences of dose interruptions, reductions and discontinuations for anaemia were 2.9%, 5.1% and 
0%, respectively; 16.2% of patients treated with olaparib needed one or more blood transfusions 
during the treatment. An exposure-response relationship between olaparib and decreases in 
haemoglobin has been demonstrated. In clinical studies with Lynparza the incidence of CTCAE grade 
≥2 shifts (decreases) from baseline in haemoglobin was 20%, absolute neutrophils 20%, platelets 5%, 
lymphocytes 30% and leucocytes 20% (all % approximate). 

The incidence of elevations in mean corpuscular volume from low or normal at baseline to above the 
ULN was approximately 55%. Levels appeared to return to normal after treatment discontinuation and 
did not appear to have any clinical consequences. 

Baseline testing, followed by monthly monitoring of complete blood counts is recommended for the 
first 12 months of treatment and periodically after this time to monitor for clinically significant 
changes in any parameter during treatment which may require dose interruption or reduction and/or 
further treatment (see sections 4.2 and 4.4).

Other laboratory findings
In clinical studies with Lynparza the incidence of CTCAE grade ≥2 shifts (elevations) from baseline in 
blood creatinine was approximately 10%. Data from a double-blind placebo-controlled study showed 
median increase up to 23% from baseline remaining consistent over time and returning to baseline 
after treatment discontinuation, with no apparent clinical sequelae. 90% of patients had creatinine 
values of CTCAE grade 0 at baseline and 10% were CTCAE grade 1 at baseline.

Gastrointestinal toxicities
Nausea was generally reported very early, with first onset within the first month of Lynparza treatment 
in the majority of patients. Vomiting was reported early, with first onset within the first two months of 
Lynparza treatment in the majority of patients. Both nausea and vomiting were reported to be 
intermittent for the majority of patients and can be managed by dose interruption, dose reduction 
and/or antiemetic therapy. Antiemetic prophylaxis is not required.

Paediatric population
No studies have been conducted in paediatric patients.

Other special populations
Limited safety data are available in elderly (age  75 years) and non-Caucasian patients.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 



10

professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V.

4.9 Overdose

Symptoms of overdose are not established and there is no specific treatment in the event of Lynparza
overdose. In the event of an overdose, physicians should follow general supportive measures and 
should treat the patient symptomatically.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antineoplastic agents, other antineoplastic agents, ATC code: L01XX46

Mechanism of action and pharmacodynamic effects
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2 
and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and 
tumour growth in vivo either as a standalone treatment or in combination with established 
chemotherapies. 

PARPs are required for the efficient repair of DNA single strand breaks and an important aspect of 
PARP-induced repair requires that after chromatin modification, PARP auto-modifies itself and 
dissociates from the DNA to facilitate access for base excision repair (BER) enzymes. When olaparib 
is bound to the active site of DNA-associated PARP it prevents the dissociation of PARP and traps it 
on the DNA, thus blocking repair. In replicating cells this leads to DNA double strand breaks (DSBs) 
when replication forks meet the PARP-DNA adduct. In normal cells, homologous recombination 
repair (HRR), which requires functional BRCA1 and 2 genes, is effective at repairing these DNA 
DSBs. In the absence of functional BRCA1 or 2, DNA DSBs cannot be repaired via HRR. Instead, 
alternative and error-prone pathways are activated, such as the non-homologous end joining (NHEJ) 
pathway, leading to increased genomic instability. After a number of rounds of replication, genomic 
instability can reach insupportable levels and result in cancer cell death, as cancer cells have a high 
DNA damage load relative to normal cells. 

In BRCA-deficient in vivo models, olaparib given after platinum treatment resulted in a delay in 
tumour progression and an increase in overall survival compared to platinum treatment alone.

Detection of BRCA mutation
Local or central testing of blood or tumour samples for BRCA1/2 mutations has been used in different 
studies. Depending on the test used and the international classification consensus, the BRCA1/2
mutations have been classified as deleterious/suspected deleterious or pathogenic/likely pathogenic. 
Genetic testing should be conducted by an experienced laboratory using a validated test.

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


11

Clinical efficacy 
The safety and efficacy of olaparib as a maintenance therapy in the treatment of platinum-sensitive 
relapsed (PSR) high grade serous ovarian, including fallopian tube or primary peritoneal cancer 
patients, following treatment with two or more platinum-containing regimens, were studied in a Phase 
II randomised, double-blind, placebo-controlled trial (study 19). The study compared the efficacy of 
olaparib maintenance treatment taken until progression with no maintenance treatment in 265 (136 
olaparib and 129 placebo) PSR serous ovarian cancer patients who were in response (CR [complete 
response] or PR [partial response]) confirmed as per RECIST and/or as per CA-125 criteria as defined 
by Gynecologic Cancer InterGroup (GCIG) (at least a 50% reduction in CA-125 levels from the last 
pre-treatment sample, confirmed 28 days later) following completion of two or more previous 
platinum-containing chemotherapy. The primary endpoint was PFS (progression-free survival) based 
on investigator assessment using RECIST 1.0. Secondary efficacy endpoints included OS (overall 
survival), DCR (disease control rate) defined as confirmed CR/PR + SD (stable disease), HRQoL 
(health related quality of life), and disease related symptoms. Exploratory analyses of time to first 
subsequent therapy or death (TFST) and time to second subsequent therapy or death (TSST- an 
approximation of PFS2) were also performed. 

Only PSR patients with partially platinum-sensitive disease (platinum-free interval of 6 to 12 months) 
and patients with platinum-sensitive disease (platinum-free interval of >12 months) who were in 
response following completion of last platinum-based chemotherapy were enrolled. Patients could not 
have received prior olaparib or other PARP inhibitor treatment. Patients could have received prior 
bevacizumab, except in the regimen immediately prior to randomisation. Retreatment with olaparib 
was not permitted following progression on olaparib. Most patients were ECOG performance status 0 
(77%), there are no data in patients with performance status 2 to 4.

Patients were randomised into the study a median of 40 days after completing their final platinum 
chemotherapy. They received an average of 3 previous chemotherapy regimens (range 2-11) and 
2.6 previous platinum-containing chemotherapies (range 2-8). Platinum-free interval was > 12 months 
in 60% and 6-12 months in 40% of the patients. Response to prior platinum chemotherapy was 
complete in 45% and partial in 55% of the patients. In the olaparib and placebo arms, 6% and 5% of 
patients had prior bevacizumab, respectively.

Patients in the olaparib group continued to receive treatment longer than those in the placebo group. A 
total of 32 (23.5%) patients received treatment for ≥2 years in the olaparib group compared with 5 
(3.9%) patients in the placebo group. A total of 18 (13.2%) patients received treatment for ≥5 years in 
the olaparib group compared with 1 (0.8%) patient in the placebo group.

The study met its primary objective demonstrating a statistically significant improvement in PFS for 
olaparib compared with placebo in the overall population with a hazard ratio (HR) of 0.35 (95% CI 
0.25-0.49; p<0.00001; median 8.4 months olaparib versus 4.8 months placebo). At the final OS
analysis (data cut off [DCO] 9 May 2016) at 79% maturity, the HR comparing olaparib with placebo 
was 0.73 (95% CI 0.55-0.95; p=0.02138 [did not meet pre-specified significance level of <0.0095]; 
median 29.8 months olaparib versus 27.8 months placebo). 

Pre-planned subgroup analysis by BRCA-mutation status identified patients with BRCA-mutated 
ovarian cancer (n=136, 51.3%) as the subgroup that derived the greatest clinical benefit from olaparib 
maintenance monotherapy. Enrolment did not require evidence of BRCA1/2 mutation (BRCA mutation 
status for some patients was determined retrospectively). There are limited data in patients with 
somatic BRCA mutated tumours; 10 patients in the olaparib arm and 10 patients in the placebo arm 
were defined as having somatic BRCA1/2 mutation. There was no strategy for multiple testing in place 
for the sub-group analyses.

In BRCA-mutated patients (n=136) there was a statistically significant improvement in PFS, TFST and 
TSST. The median PFS improvement was 6.9 months over placebo for olaparib-treated patients (HR 
0.18; 95% CI 0.10-0.31; p<0.00001; median 11.2 months versus 4.3 months). The investigator 
assessment of PFS was consistent with a blinded independent central radiological review of PFS. At 
the final analysis (DCO 9 May 2016), the time from randomisation to start of first subsequent therapy 



12

or death (TFST) was 9.4 months longer for olaparib-treated patients (HR 0.33; 95% CI 0.22–0.49; 
p<0.00001; median 15.6 months versus 6.2 months). The time from randomisation to start of second 
subsequent therapy or death (TSST) was 6.1 months longer for olaparib-treated patients (HR 0.43; 
95% CI 0.29-0.64; p=0.00003; median 21.4 months versus 15.3 months). For the secondary endpoint 
of OS, the HR for olaparib versus placebo was 0.62 (95% CI 0.42-0.93; p=0.02140; median 
34.9 months versus 30.2 months) (Table 2). In the olaparib-treated group, 28.4% of patients remained 
on treatment for ≥2 years and 14.9% for ≥5 years. In the placebo-treated group, 8.1% of patients 
remained on treatment for ≥2 years and 1.6% for ≥5 years. Within the BRCA-mutated population the 
disease control rate at 24 weeks was 57% and 24% for patients in the olaparib and placebo groups, 
respectively.

No statistically significant differences were observed between olaparib and placebo in patient reported 
symptoms or HRQoL as measured by improvement and worsening rates in the FACT/NCCN Ovarian 
Symptom Index (FOSI), Trial Outcome Index (TOI) and Functional Analysis of Cancer Therapy–
Ovarian total score (FACT-O total). 

The key efficacy findings from Study 19 for BRCA-mutated patients are presented in Table 2, and 
Figures 1 and 2. 

Table 2 Summary of key efficacy findings for patients with BRCA-mutated PSR ovarian cancer in 
Study 19

PFS (DCO 30 June 
2010)

N
(events/patients) 

(%)

Median PFS 
(months)

HRa 95% CI p-value* 

(2-sided)

Olaparib 400 mg bd 26/74 (35) 11.2
0.18 0.10-0.31 <0.00001

Placebo 46/62 (74) 4.3

TSST- an 
approximation of 
PFS2 (DCO 09 May 
2016)

N Median 
TSST 

(months)

HRa 95% CI p-value* 

(2-sided)

Olaparib 400 mg bd 53/74 (72) 21.4
0.43 0.29-0.64 0.00003

Placebo 56/62 (90) 15.3

OS (73% maturity) 
(DCO 09 May 2016)

N Median OS 
(months) HR

a 95% CI
p-value* 

(2-sided)

Olaparib 400 mg bd 49/74 (66) 34.9 
0.62 0.42-0.93 0.02140

Placebob 50/62 (81) 30.2

* There was no strategy for multiple testing in place for the sub-group analyses.
a HR= Hazard Ratio. A value < 1 favours olaparib. The analysis was performed using a Cox proportional hazards 

model with factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
b Approximately a quarter of placebo-treated patients in the BRCA-mutated subgroup (14/62; 22.6%) received a 

subsequent PARP inhibitor.
N Number of events/number of randomised patients; bd Twice daily; OS Overall survival; PFS Progression-free 

survival; CI Confidence interval; DCO Data cut off; TSST Time from randomisation to start of second subsequent 
therapy or death.



13

Figure 1 Study 19: Kaplan-Meier plot of PFS in BRCA-mutated patients (53% maturity-investigator 
assessment) 

months 0 3 6 9 12 15
n-olaparib 74 59 34 15 5 0
n-placebo 62 35 13 2 0 0

-----olaparib 400 mg bd twice daily, ____ placebo, x-axis=time from randomisation in months, y-
axis=PFS (progression-free survival), n-olaparib= number of patients at risk-olaparib, 
n-placebo=number of patients at risk-placebo

Figure 2 Study 19: Kaplan-Meier plot of OS in BRCA-mutated patients (73% maturity) 

months 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
n-

olaparib
74 69 65 56 50 39 33 27 27 27 25 23 22 16 3 0 0

n-
placebo

62 58 52 40 34 29 25 20 19 15 13 10 9 6 0 0 0

-----olaparib 400 mg bd twice daily, ____placebo, x-axis=time from randomisation in months, y-
axis=OS (overall survival), n-olaparib= number of patients at risk-olaparib, n-placebo=number of 
patients at risk-placebo



14

In Study 19, 20 patients were identified with a somatic tumour BRCA mutation (a mutation in the 
tumour but wildtype in the germline). The limited data for these somatic tumour BRCA (sBRCA) 
mutated patients show that fewer patients on olaparib reported progression events or death events 
compared with placebo (Table 3). 

Table 3 Summary of progression-free survival and overall survival: sBRCA mutated population in 
Study 19

N
events/patients

(%)
PFS
Olaparib 400 mg bd 3/10 (30%)
Placebo 8/10 (80%)
OS
Olaparib 400 mg bd 6/10 (60%)
Placebo 8/10 (80%)

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with 
Lynparza in all subsets of the paediatric population, in ovarian carcinoma (excluding 
rhabdomyosarcoma and germ cell tumours) (see section 4.2 for information on paediatric use). 

5.2 Pharmacokinetic properties

The pharmacokinetics of olaparib at the 400 mg twice daily capsule dose are characterised by an 
apparent plasma clearance of ~8.6 L/h, an apparent volume of distribution of ~167 L and a terminal 
half-life of 11.9 hours.

Absorption
Following oral administration of olaparib via the capsule formulation, absorption is rapid with peak 
plasma concentrations typically achieved between 1 to 3 hours after dosing. On multiple dosing there 
is no marked accumulation, with steady state exposures achieved within ~3 to 4 days. 

Co-administration with food slowed the rate (tmax delayed by 2 hours) and marginally increased the 
extent of absorption of olaparib (AUC increased by approximately 20%). Therefore, it is 
recommended that patients take Lynparza at least one hour after food, and refrain from eating 
preferably for up to 2 hours afterwards (see section 4.2).

Distribution
The in vitro protein binding is approximately 82% at clinically relevant concentrations of 10 µg/mL.

In vitro, human plasma protein binding of olaparib was dose-dependent; the fraction bound was 
approximately 91% at 1 µg/mL, reducing to 82% at 10 µg/mL and to 70% at 40 µg/mL. In solutions of 
purified proteins, the olaparib fraction bound to albumin was approximately 56%, which was 
independent of olaparib concentrations. Using the same assay, the fraction bound to alpha-1 acid 
glycoprotein was 29% at 10 µg/mL with a trend of decreased binding at higher concentrations.

Biotransformation
In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of 
olaparib (see section 4.5).

Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the 
majority of the circulating radioactivity in plasma (70%) and was the major component found in both 
urine and faeces (15% and 6% of the dose, respectively). The metabolism of olaparib is extensive. The 
majority of the metabolism was attributable to oxidation reactions with a number of the components 



15

produced undergoing subsequent glucuronide or sulfate conjugation. Up to 20, 37 and 20 metabolites 
were detected in plasma, urine and faeces respectively, the majority of them representing <1% of the 
dosed material. A ring-opened piperazin-3-ol moiety, and two mono-oxygenated metabolites (each 
~10%) were the major circulating components, with one of the mono-oxygenated metabolites also 
being the major metabolite in the excreta (6% and 5% of the urinary and faecal radioactivity,
respectively). 

In vitro, olaparib produced little/no inhibition of UGT1A4, UGT1A9, UGT2B7, or CYPs 1A2, 2A6, 
2B6, 2C8, 2C9, 2C19, 2D6 or 2E1 and is not expected to be a clinically significant time dependent 
inhibitor of any of these CYP enzymes. Olaparib inhibited UGT1A1 in vitro, however, PBPK 
simulations suggest this is not of clinical importance. In vitro, olaparib is a substrate of the efflux 
transporter P-gp, however this is unlikely to be of clinical significance (see section 4.5).

In vitro, data also show that olaparib is not a substrate for OATP1B1, OATP1B3, OCT1, BCRP or 
MRP2, and is not an inhibitor of OATP1B3, OAT1 or MRP2.

Elimination
Following a single dose of 14C-olaparib, ~86% of the dosed radioactivity was recovered within a 7-day 
collection period, ~44% via the urine and ~42% via the faeces. Majority of the material was excreted 
as metabolites. 

Special populations
In population based PK analyses, patient age, bodyweight or race (including White and Japanese 
patients) were not significant covariates.

Renal impairment
In patients with mild renal impairment (creatinine clearance 51 to 80 ml/min), AUC increased by 24% 
and Cmax by 15% compared with patients with normal renal function. No Lynparza dose adjustment is 
required for patients with mild renal impairment.

In patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min), AUC increased by 
44% and Cmax by 26% compared with patients with normal renal function. Lynparza dose adjustment 
is recommended for patients with moderate renal impairment (see section 4.2).

There are no data in patients with severe impairment or end-stage renal disease (creatinine 
clearance <30 ml/min).

Hepatic impairment
In patients with mild hepatic impairment (Child-Pugh classification A), AUC increased by 15% and 
Cmax by 13% and in patients with moderate hepatic impairment (Child-Pugh classification B), AUC 
increased by 8% and Cmax decreased by 13% compared with patients with normal hepatic function. No 
Lynparza dose adjustment is required for patients with mild or moderate hepatic impairment (see 
section 4.2). There are no data in patients with severe hepatic impairment (Child-Pugh 
classification C).

Paediatric population
No studies have been conducted to investigate the pharmacokinetics of olaparib in paediatric patients.

5.3 Preclinical safety data

Genotoxicity
Olaparib showed no mutagenic potential, but was clastogenic in mammalian cells in vitro. When 
dosed orally to rats, olaparib induced micronuclei in bone marrow. This clastogenicity is consistent 
with the known pharmacology of olaparib and indicates potential for genotoxicity in man.



16

Repeat-dose toxicity
In repeat-dose toxicity studies of up to 6 months duration in rats and dogs, daily oral doses of olaparib 
were well-tolerated. The major primary target organ for toxicity in both species was the bone marrow, 
with associated changes in peripheral haematology parameters. These changes were reversible within 
4 weeks of cessation of dosing. In rats, minimal degenerative effects on gastrointestinal tract were also 
noted. These findings occurred at exposures below those seen clinically. Studies using human bone 
marrow cells also showed that direct exposure to olaparib can result in toxicity to bone marrow cells in 
ex vivo assays.

Reproductive toxicology
In a female fertility study where rats were dosed until implantation, although extended oestrus was 
observed in some animals, mating performance and pregnancy rate was not affected. However, there 
was a slight reduction in embryofoetal survival.

In rat embryofoetal development studies, and at dose levels that did not induce significant maternal 
toxicity, olaparib caused reduced embryofoetal survival, reduced foetal weight and foetal 
developmental abnormalities, including major eye malformations (e.g. anophthalmia, 
microphthalmia), vertebral/rib malformation and visceral and skeletal abnormalities. 

Carcinogenicity
Carcinogenicity studies have not been conducted with olaparib.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule content
Lauroyl macrogol-32 glycerides 

Capsule shell
Hypromellose 
Titanium dioxide (E171)
Gellan gum (E418)
Potassium acetate

Printing ink
Shellac
Iron oxide black (E172)

6.2 Incompatibilities

Not applicable. 

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

Do not freeze. Any capsules that have been frozen must be discarded.

Lynparza capsules can be stored for up to 3 months below 30°C. The capsules must be discarded after 
this period.



17

6.5 Nature and contents of container 

HDPE plastic bottle with a child-resistant closure containing 112 hard capsules. 
Pack of 448 capsules (4 bottles of 112 capsules).

6.6 Special precautions for disposal 

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

7. MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

8. MARKETING AUTHORISATION NUMBER(S) 

EU/1/14/959/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16 December 2014
Date of latest renewal: 1 October 2019

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu.

http://www.ema.europa.eu/


18

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 100 mg film-coated tablets

Lynparza 150 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lynparza 100 mg film-coated tablets
Each film-coated tablet contains 100 mg olaparib.

Lynparza 150 mg film-coated tablets
Each film-coated tablet contains 150 mg olaparib.

Excipient with known effect:
This medicinal product contains 0.24 mg sodium per 100 mg tablet and 0.35 mg sodium per 150 mg 
tablet.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).

Lynparza 100 mg film-coated tablets
Yellow to dark yellow, oval, bi-convex tablet, debossed with ‘OP100’ on one side and plain on the 
other side.

Lynparza 150 mg film-coated tablets
Green to green/grey, oval, bi-convex tablet, debossed with ‘OP150’ on one side and plain on the other 
side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ovarian cancer
Lynparza is indicated as monotherapy for the:

 maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-
mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary 
peritoneal cancer who are in response (complete or partial) following completion of first-line 
platinum-based chemotherapy.

 maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial 
ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) 
to platinum-based chemotherapy.



19

Breast cancer
Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-
mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should 
have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic 
setting unless patients were not suitable for these treatments (see section 5.1).

Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after 
prior endocrine therapy, or be considered unsuitable for endocrine therapy.

Adenocarcinoma of the pancreas
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline 
BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed 
after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

4.2 Posology and method of administration

Treatment with Lynparza should be initiated and supervised by a physician experienced in the use of 
anticancer medicinal products.

Detection of BRCA1/2 mutations

First-line maintenance treatment of BRCA-mutated advanced ovarian cancer:
Before Lynparza treatment is initiated for first-line maintenance treatment of high-grade epithelial 
ovarian cancer (EOC), fallopian tube cancer (FTC) or primary peritoneal cancer (PPC), patients must 
have confirmation of deleterious or suspected deleterious germline and/or somatic mutations in the 
breast cancer susceptibility genes (BRCA) 1 or 2 using a validated test.

Maintenance treatment of platinum-sensitive relapsed ovarian cancer:
There is no requirement for BRCA1/2 testing prior to using Lynparza for the maintenance treatment of 
relapsed EOC, FTC or PPC who are in a complete or partial response to platinum-based therapy.

gBRCA1/2-mutated HER2-negative metastatic breast cancer:
For germline breast cancer susceptibility genes (gBRCA1/2) mutated human epidermal growth factor 
receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, patients must have 
confirmation of a deleterious or suspected deleterious gBRCA1/2 mutation before Lynparza treatment 
is initiated. gBRCA1/2 mutation status should be determined by an experienced laboratory using a 
validated test method. Data demonstrating clinical validation of tumour BRCA1/2 tests in breast cancer 
are not currently available.

First-line maintenance treatment of gBRCA-mutated metastatic adenocarcinoma of the pancreas:
For first-line maintenance treatment of germline BRCA1/2-mutated metastatic adenocarcinoma of the 
pancreas, patients must have confirmation of a deleterious or suspected deleterious gBRCA1/2 
mutation before Lynparza treatment is initiated. gBRCA1/2 mutation status should be determined by 
an experienced laboratory using a validated test method. Data demonstrating clinical validation of 
tumour BRCA1/2 tests in adenocarcinoma of the pancreas are not currently available.

Genetic counselling for patients tested for mutations in BRCA1/2 genes should be performed 
according to local regulations.

Posology

Lynparza is available as 100 mg and 150 mg tablets.

The recommended dose of Lynparza is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a 
total daily dose of 600 mg. The 100 mg tablet is available for dose reduction.



20

Patients with platinum-sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy
should start treatment with Lynparza no later than 8 weeks after completion of their final dose of the 
platinum-containing regimen. 

Duration of treatment

First-line maintenance treatment of BRCA-mutated advanced ovarian cancer:
Patients can continue treatment until radiological disease progression, unacceptable toxicity or for up 
to 2 years if there is no radiological evidence of disease after 2 years of treatment. Patients with 
evidence of disease at 2 years, who in the opinion of the treating physician can derive further benefit 
from continuous treatment, can be treated beyond 2 years.

Maintenance treatment of platinum-sensitive relapsed ovarian cancer:
For patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary 
peritoneal cancer, it is recommended that treatment be continued until progression of the underlying 
disease or unacceptable toxicity.

gBRCA1/2-mutated HER2-negative metastatic breast cancer:
It is recommended that treatment be continued until progression of the underlying disease or 
unacceptable toxicity. 

First-line maintenance treatment of gBRCA-mutated metastatic adenocarcinoma of the pancreas:
It is recommended that treatment be continued until progression of the underlying disease or 
unacceptable toxicity. 

There are no efficacy or safety data on maintenance retreatment with Lynparza following first or 
subsequent relapse in ovarian cancer patients or on retreatment of breast cancer patients (see 
section 5.1).

Important differences in posology between Lynparza tablets and capsules 
Lynparza tablets (100 mg and 150 mg) should not be substituted for Lynparza capsules (50 mg) on a 
milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. 
Therefore, the specific dose recommendations for each formulation should be followed.

Missing dose
If a patient misses a dose of Lynparza, they should take their next normal dose at its scheduled time.

Dose adjustments for adverse reactions
Treatment may be interrupted to manage adverse reactions such as nausea, vomiting, diarrhoea, and 
anaemia and dose reduction can be considered (see section 4.8).

The recommended dose reduction is to 250 mg (one 150 mg tablet and one 100 mg tablet) twice daily 
(equivalent to a total daily dose of 500 mg).

If a further dose reduction is required, then reduction to 200 mg (two 100 mg tablets) twice daily 
(equivalent to a total daily dose of 400 mg) is recommended.

Dose adjustments for co-administration with CYP3A inhibitors
Concomitant use of strong or moderate CYP3A inhibitors is not recommended and alternative agents 
should be considered. If a strong CYP3A inhibitor must be co-administered, the recommended 
Lynparza dose reduction is to 100 mg (one 100 mg tablet) taken twice daily (equivalent to a total daily 
dose of 200 mg). If a moderate CYP3A inhibitor must be co-administered, the recommended Lynparza 
dose reduction is to 150 mg (one 150 mg tablet) taken twice daily (equivalent to a total daily dose of 
300 mg) (see sections 4.4 and 4.5).



21

Special populations

Elderly 
No adjustment in starting dose is required for elderly patients. There are limited clinical data in 
patients aged 75 years and over. 

Renal impairment 
For patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min) the recommended 
dose of Lynparza is 200 mg (two 100 mg tablets) twice daily (equivalent to a total daily dose of 
400 mg) (see section 5.2). 

Lynparza can be administered in patients with mild renal impairment (creatinine clearance 51 to 
80 ml/min) with no dose adjustment.

Lynparza is not recommended for use in patients with severe renal impairment or end-stage renal 
disease (creatinine clearance ≤ 30 ml/min), as safety and pharmacokinetics have not been studied in 
these patients. Lynparza may only be used in patients with severe renal impairment if the benefit 
outweighs the potential risk, and the patient should be carefully monitored for renal function and 
adverse events. 

Hepatic impairment 
Lynparza can be administered to patients with mild or moderate hepatic impairment (Child-Pugh 
classification A or B) with no dose adjustment (see section 5.2). Lynparza is not recommended for use 
in patients with severe hepatic impairment (Child-Pugh classification C), as safety and 
pharmacokinetics have not been studied in these patients. 

Non-Caucasian patients
There are limited clinical data available in non-Caucasian patients. However, no dose adjustment is 
required on the basis of ethnicity (see section 5.2). 

Paediatric population
The safety and efficacy of Lynparza in children and adolescents have not been established. 
No data are available.

Method of administration 

Lynparza is for oral use.

Lynparza tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Lynparza 
tablets may be taken without regard to meals.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Breast-feeding during treatment and for 1 month after the last dose (see section 4.6).

4.4 Special warnings and precautions for use

Haematological toxicity 
Haematological toxicity has been reported in patients treated with Lynparza, including clinical 
diagnoses and/or laboratory findings of generally mild or moderate (CTCAE grade 1 or 2) anaemia, 
neutropenia, thrombocytopenia and lymphopenia. Patients should not start treatment with Lynparza 
until they have recovered from haematological toxicity caused by previous anticancer therapy 
(haemoglobin, platelet and neutrophil levels should be ≤CTCAE grade 1). Baseline testing, followed 
by monthly monitoring, of complete blood counts is recommended for the first 12 months of treatment 



22

and periodically after this time to monitor for clinically significant changes in any parameter during 
treatment (see section 4.8).

If a patient develops severe haematological toxicity or blood transfusion dependence, treatment with 
Lynparza should be interrupted and appropriate haematological testing should be initiated. If the blood 
parameters remain clinically abnormal after 4 weeks of Lynparza dose interruption, bone marrow 
analysis and/or blood cytogenetic analysis are recommended. 

Myelodysplastic syndrome/Acute myeloid leukaemia 
The overall incidence of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) in patients 
treated in clinical trials with Lynparza monotherapy, including long-term survival follow-up, was 
<1.5% and the majority of events had a fatal outcome. The duration of therapy with olaparib in 
patients who developed MDS/AML varied from <6 months to >2 years; data with longer durations of 
exposure are limited. All patients had potential contributing factors for the development of 
MDS/AML, having received previous chemotherapy with platinum agents. Many had also received 
other DNA damaging agents and radiotherapy. The majority of reports were in germline breast cancer 
susceptibility gene 1 or 2 (gBRCA1/2) mutation carriers. The incidence of MDS/AML cases was 
similar among gBRCA1m and gBRCA2m patients (1.7% and 1.4%, respectively). Some of the patients 
had a history of previous cancer or of bone marrow dysplasia. If MDS and/or AML are confirmed 
while on treatment with Lynparza, it is recommended that Lynparza should be discontinued and the 
patient be treated appropriately.

Pneumonitis 
Pneumonitis, including events with a fatal outcome, has been reported in <1.0% of patients treated 
with Lynparza in clinical studies. Reports of pneumonitis had no consistent clinical pattern and were 
confounded by a number of pre-disposing factors (cancer and/or metastases in lungs, underlying 
pulmonary disease, smoking history, and/or previous chemotherapy and radiotherapy). If patients 
present with new or worsening respiratory symptoms such as dyspnoea, cough and fever, or an 
abnormal chest radiologic finding is observed, Lynparza treatment should be interrupted and prompt 
investigation initiated. If pneumonitis is confirmed, Lynparza treatment should be discontinued and 
the patient treated appropriately.

Embryofoetal toxicity
Based on its mechanism of action (PARP inhibition), Lynparza could cause foetal harm when 
administered to a pregnant woman. Nonclinical studies in rats have shown that olaparib causes adverse 
effects on embryofoetal survival and induces major foetal malformations at exposures below those 
expected at the recommended human dose of 300 mg twice daily.

Pregnancy/contraception
Lynparza should not be used during pregnancy. Women of childbearing potential must use two forms 
of reliable contraception before starting Lynparza treatment, during therapy and for 1 month after 
receiving the last dose of Lynparza. Two highly effective and complementary forms of contraception 
are recommended. Male patients and their female partners of childbearing potential should use reliable 
contraception during therapy and for 3 months after receiving the last dose of Lynparza (see 
section 4.6).

Interactions 
Lynparza co-administration with strong or moderate CYP3A inhibitors is not recommended (see 
section 4.5). If a strong or moderate CYP3A inhibitor must be co-administered, the dose of Lynparza 
should be reduced (see sections 4.2 and 4.5).

Lynparza co-administration with strong or moderate CYP3A inducers is not recommended. In the 
event that a patient already receiving Lynparza requires treatment with a strong or moderate CYP3A 
inducer, the prescriber should be aware that the efficacy of Lynparza may be substantially reduced 
(see section 4.5).



23

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, that is 
to say essentially “sodium-free”.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions
Clinical studies of olaparib in combination with other anticancer medicinal products, including DNA 
damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. The 
recommended Lynparza monotherapy dose is not suitable for combination with myelosuppressive 
anticancer medicinal products.

Combination of olaparib with vaccines or immunosuppressant agents has not been studied. Therefore, 
caution should be taken if these medicinal products are co-administered with Lynparza and patients 
should be closely monitored.

Pharmacokinetic interactions
Effect of other medicinal products on olaparib
CYP3A4/5 are the isozymes predominantly responsible for the metabolic clearance of olaparib.

A clinical study to evaluate the impact of itraconazole, a known CYP3A inhibitor, has shown that 
co-administration with olaparib increased mean olaparib Cmax by 42% (90% CI: 33-52%) and mean 
AUC by 170% (90% CI: 144-197%). Therefore, known strong (e.g. itraconazole, telithromycin, 
clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir) or 
moderate (e.g. erythromycin, diltiazem, fluconazole, verapamil) inhibitors of this isozyme are not 
recommended with Lynparza (see section 4.4). If strong or moderate CYP3A inhibitors must be 
co-administered, the dose of Lynparza should be reduced. The recommended Lynparza dose reduction 
is to 100 mg taken twice daily (equivalent to a total daily dose of 200 mg) with a strong CYP3A 
inhibitor or 150 mg taken twice daily (equivalent to a total daily dose of 300 mg) with a moderate 
CYP3A inhibitor (see sections 4.2 and 4.4). It is also not recommended to consume grapefruit juice 
while on Lynparza therapy as it is a CYP3A inhibitor.

A clinical study to evaluate the impact of rifampicin, a known CYP3A inducer, has shown that 
co-administration with olaparib decreased olaparib mean Cmax by 71% (90% CI: 76-67%) and mean 
AUC by 87% (90% CI: 89-84%). Therefore, known strong inducers of this isozyme (e.g. phenytoin, 
rifampicin, rifapentine, carbamazepine, nevirapine, phenobarbital and St John’s Wort) are not 
recommended with Lynparza, as it is possible that the efficacy of Lynparza could be substantially 
reduced. The magnitude of the effect of moderate to strong inducers (e.g. efavirenz, rifabutin) on 
olaparib exposure is not established, therefore the co-administration of Lynparza with these medicinal 
products is also not recommended (see section 4.4).

Effect of olaparib on other medicinal products
Olaparib inhibits CYP3A4 in vitro and is predicted to be a mild CYP3A inhibitor in vivo. Therefore, 
caution should be exercised when sensitive CYP3A substrates or substrates with a narrow therapeutic 
margin (e.g. simvastatin, cisapride, cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, 
tacrolimus and quetiapine) are combined with olaparib. Appropriate clinical monitoring is 
recommended for patients receiving CYP3A substrates with a narrow therapeutic margin 
concomitantly with olaparib.

Induction of CYP1A2, 2B6 and 3A4 has been shown in vitro with CYP2B6 being most likely to be 
induced to a clinically relevant extent. The potential for olaparib to induce CYP2C9, CYP2C19 and 
P-gp can also not be excluded. Therefore, olaparib upon co-administration may reduce the exposure to 
substrates of these metabolic enzymes and transport protein. The efficacy of some hormonal 
contraceptives may be reduced if co-administered with olaparib (see sections 4.4 and 4.6).



24

In vitro, olaparib inhibits the efflux transporter P-gp (IC50 = 76 µM), therefore it cannot be excluded 
that olaparib may cause clinically relevant drug interactions with substrates of P-gp (e.g. simvastatin, 
pravastatin, dabigatran, digoxin and colchicine). Appropriate clinical monitoring is recommended for 
patients receiving this type of medicinal product concomitantly.

In vitro, olaparib has been shown to be an inhibitor of BCRP, OATP1B1, OCT1, OCT2, OAT3, 
MATE1 and MATE2K. It cannot be excluded that olaparib may increase the exposure to substrates of 
BCRP (e.g. methotrexate, rosuvastatin), OATP1B1 (e.g. bosentan, glibenclamide, repaglinide, statins 
and valsartan), OCT1 (e.g. metformin), OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide and 
methotrexate), MATE1 (e.g. metformin) and MATE2K (e.g. metformin). In particular, caution should 
be exercised if olaparib is administered in combination with any statin. 

Combination with anastrozole, letrozole and tamoxifen
A clinical study has been performed to assess the combination of olaparib with anastrozole, letrozole 
or tamoxifen. No significant interaction was observed with anastrozole or letrozole, whereas 
tamoxifen decreased exposure to olaparib by 27%. The clinical relevance of this effect is unknown. 
Olaparib does not affect the pharmacokinetics of tamoxifen.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/contraception in females
Women of childbearing potential should not become pregnant while on Lynparza and not be pregnant 
at the beginning of treatment. A pregnancy test should be performed on all women of childbearing 
potential prior to treatment and considered regularly throughout treatment. 

Women of childbearing potential must use two forms of reliable contraception before starting 
Lynparza therapy, during therapy and for 1 month after receiving the last dose of Lynparza, unless 
abstinence is the chosen method of contraception (see section 4.4). Two highly effective and 
complementary forms of contraception are recommended.

Since it cannot be excluded that olaparib may reduce exposure to substrates of CYP2C9 through 
enzyme induction, the efficacy of some hormonal contraceptives may be reduced if co-administered 
with olaparib. Therefore, an additional non-hormonal contraceptive method should be considered 
during treatment (see section 4.5). For women with hormone dependent cancer, two non-hormonal 
contraceptive methods should be considered.

Contraception in males 
It is not known whether olaparib or its metabolites are found in seminal fluid. Male patients must use a 
condom during therapy and for 3 months after receiving the last dose of Lynparza when having sexual 
intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of 
male patients must also use highly effective contraception if they are of childbearing potential (see 
section 4.4). Male patients should not donate sperm during therapy and for 3 months after receiving 
the last dose of Lynparza. 

Pregnancy
Studies in animals have shown reproductive toxicity including serious teratogenic effects and effects 
on embryofoetal survival in the rat at maternal systemic exposures lower than those in humans at 
therapeutic doses (see section 5.3). There are no data from the use of olaparib in pregnant women, 
however, based on the mode of action of olaparib, Lynparza should not be used during pregnancy and 
in women of childbearing potential not using reliable contraception during therapy and for 1 month 
after receiving the last dose of Lynparza. (See previous paragraph: “Women of childbearing 
potential/contraception in females” for further information about birth control and pregnancy testing.)



25

Breast-feeding
There are no animal studies on the excretion of olaparib in breast milk. It is unknown whether olaparib
or its metabolites are excreted in human milk. Lynparza is contraindicated during breast-feeding and 
for 1 month after receiving the last dose, given the pharmacologic property of the product (see 
section 4.3). 

Fertility
There are no clinical data on fertility. In animal studies, no effect on conception was observed but 
there are adverse effects on embryofoetal survival (see section 5.3). 

4.7 Effects on ability to drive and use machines

Lynparza has moderate influence on the ability to drive and use machines. Patients who take Lynparza 
may experience fatigue, asthenia or dizziness. Patients who experience these symptoms should 
observe caution when driving or using machines. 

4.8 Undesirable effects

Summary of the safety profile
Lynparza monotherapy has been associated with adverse reactions generally of mild or moderate 
severity (CTCAE grade 1 or 2) and generally not requiring treatment discontinuation. The most 
frequently observed adverse reactions across clinical trials in patients receiving Lynparza 
monotherapy (≥ 10%) were nausea, fatigue, vomiting, anaemia, diarrhoea, decreased appetite, 
headache, dysgeusia, neutropenia, cough, dyspnoea, dizziness, dyspepsia, leukopenia, 
thrombocytopenia and upper abdominal pain.

The Grade ≥ 3 adverse reactions occurring in > 2% of patients were anaemia (16%), neutropenia (6%),
fatigue/asthenia (6%), leukopenia (3%), thrombocytopenia (3%) and vomiting (2%).

Adverse reactions that most commonly led to dose interruptions and/ or reductions were anaemia 
(14.9%), vomiting (7.2%), nausea (6.5%), fatigue/asthenia (6.2%) and neutropenia (6.2%). Adverse 
reactions that most commonly led to permanent discontinuation were anaemia (1.2%), nausea (0.7%), 
thrombocytopenia (0.6%) and vomiting (0.6%).

Tabulated list of adverse reactions
The safety profile is based on pooled data from 2095 patients with solid tumours treated with 
Lynparza monotherapy in clinical trials at the recommended dose.

The following adverse reactions have been identified in clinical trials with patients receiving Lynparza
monotherapy where patient exposure is known. Adverse drug reactions are listed by MedDRA System 
Organ Class (SOC) and then by MedDRA preferred term in Table 1. Within each SOC, preferred 
terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of 
occurrence of adverse reactions are defined as: very common (≥1/10); common (1/100 to <1/10); 
uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1000); very rare (<1/10,000); not known 
(cannot be estimated from available data).



26

Table 1 Tabulated list of adverse reactions

Adverse reactions

MedDRA 
System Organ 
Class

Frequency of All CTCAE grades Frequency of CTCAE grade 3 
and above 

Blood and 
lymphatic 
system disorders

Very common
Anaemiaa, Neutropeniaa, 
Thrombocytopeniaa, Leukopeniaa

Common
Lymphopeniaa

Very common
Anaemiaa

Common
Neutropeniaa, 
Thrombocytopeniaa, 
Leukopeniaa

Uncommon
Lymphopeniaa

Immune system 
disorders

Common
Rasha

Uncommon
Hypersensitivitya, Dermatitisa

-

Metabolism and 
nutrition 
disorders

Very common 
Decreased appetite

Uncommon
Decreased appetite

Nervous system 
disorders

Very common
Dizziness, Headache, Dysgeusia 

Uncommon
Dizziness, Headache

Respiratory, 
thoracic and 
mediastinal 
disorders

Very common
Cougha, Dyspnoeaa

Common

Dyspnoeaa

Uncommon
Cougha

Gastrointestinal 
disorders

Very common
Vomiting, Diarrhoea, Nausea, Dyspepsia,
Upper abdominal pain

Common
Stomatitisa

Common
Vomiting, Diarrhoea, Nausea

Uncommon
Stomatitisa, Upper abdominal 
pain

General 
disorders and 
administration 
site conditions

Very common
Fatigue (including asthenia) 

Common
Fatigue (including asthenia)

Investigations Common
Blood creatinine increased

Uncommon 
Mean cell volume increased

Uncommon 
Blood creatinine increased

a Anaemia includes preferred terms (PTs) of anaemia, anaemia macrocytic, erythropenia, haematocrit decreased, 

haemoglobin decreased, normochromic anaemia, normochromic normocytic anaemia, normocytic anaemia and red 

blood cell count decreased; Neutropenia includes PTs of agranulocytosis, febrile neutropenia, granulocyte count 

decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection, neutropenic sepsis and 

neutrophil count decreased; Thrombocytopenia includes PTs of platelet count decreased, platelet production 

decreased, plateletcrit decreased and thrombocytopenia; Leukopenia includes PTs of leukopenia and white blood cell 

count decreased; Lymphopenia includes PTs of B-lymphocyte count decreased, lymphocyte count decreased,



27

lymphopenia and T-lymphocyte count decreased; Cough includes PTs of cough and productive cough; Rash includes 

PTs of exfoliative rash, generalised erythema, rash, rash erythematous, rash generalised, rash macular, rash 

maculo-papular, rash papular and rash pruritic; Hypersensitivity includes PTs of drug hypersensitivity and

hypersensitivity; Dermatitis includes PTs of dermatitis, dermatitis allergic and dermatitis exfoliative. Dyspnoea 

includes PTs of dyspnoea and dyspnoea exertional; Stomatitis includes PTs of aphthous ulcer, mouth ulceration and 

stomatitis.

Description of selected adverse reactions

Haematological toxicity
Anaemia and other haematological toxicities were generally low grade (CTCAE grade 1 or 2), 
however, there were reports of CTCAE grade 3 and higher events. Anaemia was the most common 
CTCAE grade ≥3 adverse reaction reported in clinical studies. Median time to first onset of anaemia 
was approximately 4 weeks (approximately 7 weeks for CTCAE grade ≥3 events). Anaemia was 
managed with dose interruptions and dose reductions (see section 4.2), and where appropriate with 
blood transfusions. In clinical studies with the tablet formulation, the incidence of anaemia adverse 
reactions was 38.8% (CTCAE grade ≥3 17.4%) and the incidences of dose interruptions, reductions
and discontinuations for anaemia were 15.7%, 10.8% and 1.9%, respectively; 20.9% of patients 
treated with olaparib needed one or more blood transfusions. An exposure-response relationship 
between olaparib and decreases in haemoglobin has been demonstrated. In clinical studies with 
Lynparza the incidence of CTCAE grade ≥ 2 shifts (decreases) from baseline in haemoglobin was 
20%, absolute neutrophils 20%, platelets 5%, lymphocytes 30% and leucocytes 20% (all % 
approximate).

The incidence of elevations in mean corpuscular volume from low or normal at baseline to above the 
ULN was approximately 55%. Levels appeared to return to normal after treatment discontinuation and 
did not appear to have any clinical consequences.

Baseline testing, followed by monthly monitoring of complete blood counts is recommended for the 
first 12 months of treatment and periodically after this time to monitor for clinically significant 
changes in any parameter during treatment which may require dose interruption or reduction and/or 
further treatment (see sections 4.2 and 4.4).

Other laboratory findings
In clinical studies with Lynparza the incidence of CTCAE grade ≥ 2 shifts (elevations) from baseline 
in blood creatinine was approximately 10%. Data from a double-blind placebo-controlled study 
showed median increase up to 23% from baseline remaining consistent over time and returning to 
baseline after treatment discontinuation, with no apparent clinical sequelae. 90% of patients had 
creatinine values of CTCAE grade 0 at baseline and 10% were CTCAE grade 1 at baseline.

Gastrointestinal toxicities
Nausea was generally reported very early, with first onset within the first month of Lynparza treatment 
in the majority of patients. Vomiting was reported early, with first onset within the first two months of 
Lynparza treatment in the majority of patients. Both nausea and vomiting were reported to be 
intermittent for the majority of patients and can be managed by dose interruption, dose reduction 
and/or antiemetic therapy. Antiemetic prophylaxis is not required.

In first-line ovarian cancer maintenance treatment, patients experienced nausea events (77% on 
olaparib, 38% on placebo), vomiting (40% on olaparib, 15% on placebo), diarrhoea (34% on olaparib, 
25% on placebo) and dyspepsia (17% on olaparib, 12% on placebo). Nausea events led to 
discontinuation in 2.3% of olaparib-treated patients (CTCAE Grade 2) and 0.8% of placebo-treated 
patients (CTCAE Grade 1); 0.8% and 0.4% of olaparib-treated patients discontinued treatment due to 
low grade (CTCAE Grade 2) vomiting and dyspepsia, respectively. No olaparib or placebo-treated 
patients discontinued due to diarrhoea. No placebo-treated patients discontinued due to vomiting or 
dyspepsia. Nausea events led to dose interruption and dose reductions in 14% and 4%, respectively, of 



28

olaparib-treated patients. Vomiting events led to interruption in 10% of olaparib-treated patients; no 
olaparib-treated patients experienced a vomiting event leading to dose reduction. 

Paediatric population
No studies have been conducted in paediatric patients.

Other special populations
Limited safety data are available in elderly (age  75 years) and non-Caucasian patients.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V.

4.9 Overdose

There is limited experience of overdose with olaparib. No unexpected adverse reactions were reported 
in a small number of patients who took a daily dose of up to 900 mg of olaparib tablets over two days. 
Symptoms of overdose are not established and there is no specific treatment in the event of Lynparza
overdose. In the event of an overdose, physicians should follow general supportive measures and 
should treat the patient symptomatically.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antineoplastic agents, other antineoplastic agents, ATC code: L01XX46

Mechanism of action and pharmacodynamic effects
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, 
and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and 
tumour growth in vivo either as a standalone treatment or in combination with established 
chemotherapies. 

PARPs are required for the efficient repair of DNA single strand breaks and an important aspect of 
PARP-induced repair requires that after chromatin modification, PARP auto-modifies itself and 
dissociates from the DNA to facilitate access for base excision repair (BER) enzymes. When olaparib 
is bound to the active site of DNA-associated PARP it prevents the dissociation of PARP and traps it 
on the DNA, thus blocking repair. In replicating cells this also leads to the formation of DNA 
double-strand breaks (DSBs) when replication forks meet the PARP-DNA adducts. In normal cells, 
homologous recombination repair (HRR) pathway is effective at repairing these DNA DSBs. In 
cancers that lack functional components of HRR such as BRCA1 or 2, DNA DSBs cannot be repaired 
accurately or effectively. Instead, alternative and error-prone pathways are activated, such as the 
classical non-homologous end joining (NHEJ) pathway, leading to increased genomic instability. 
After a number of rounds of replication, genomic instability can reach insupportable levels and result 
in cancer cell death, as cancer cells already have a high DNA damage load relative to normal cells. In 
the absence of BRCA1 or BRCA2 mutations, HRR pathway may be compromised by other 
mechanisms, although the causative aberrancy and penetrance are not fully elucidated. Absence of 
fully functional HRR pathway is one of the key determinants of platinum sensitivity in ovarian and 
other cancers.

In BRCA1/2-deficient in vivo models, olaparib given after platinum treatment resulted in a delay in 
tumour progression and an increase in overall survival compared to platinum treatment alone that 
correlated with the period of olaparib maintenance treatment.

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


29

Detection of BRCA1/2 mutations
Local or central testing of blood and/or tumour samples for BRCA1/2 mutations have been used in 
different studies. Depending on the test used and the international classification consensus, the 
BRCA1/2 mutations have been classified as deleterious/suspected deleterious or pathogenic/likely 
pathogenic. Genetic testing should be conducted by an experienced laboratory using a validated test.

Clinical efficacy and safety

First-line maintenance treatment of BRCA-mutated advanced ovarian cancer:
SOLO1 Study

The safety and efficacy of olaparib as maintenance therapy were studied in patients with newly 
diagnosed advanced (FIGO Stage III-IV) high-grade serous or endometrioid BRCA1/2 mutated 
(BRCA1/2m) ovarian cancer following completion of first-line platinum-based chemotherapy in a 
Phase III randomised, double-blind, placebo-controlled, multicentre trial. In this study 391 patients 
were randomised 2:1 to receive either Lynparza (300 mg [2 x 150 mg tablets] twice daily) or placebo.
Patients were stratified by response to first-line platinum chemotherapy; complete response (CR) or 
partial response (PR). Treatment was continued until radiological progression of the underlying 
disease, unacceptable toxicity or for up to 2 years. For patients who remained in complete clinical 
response (i.e. no radiological evidence of disease), the maximum duration of treatment was 2 years; 
however, patients who had evidence of disease that remained stable (i.e. no evidence of disease 
progression) could continue to receive Lynparza beyond 2 years.

Patients with germline or somatic BRCA1/2 mutations were identified prospectively either from 
germline testing in blood via a local test (n=208) or central test (n=181) or from testing a tumour 
sample using a local test (n=2). By central germline testing, deleterious or suspected deleterious 
mutations were identified in 95.3% (365/383) and 4.7% (18/383) of patients, respectively. Large 
rearrangements in the BRCA1/2 genes were detected in 5.5% (21/383) of the randomised patients. The 
gBRCAm status of patients enrolled via local testing was confirmed retrospectively by central testing. 
Retrospective testing of patients with available tumour samples was performed using central testing 
and generated successful results in 341 patients, of which 95% had an eligible mutation (known 
[n=47] or likely pathogenic [n=277]) and 2 gBRCAwt patients were confirmed to have sBRCAm only.
There were 389 patients who were germline BRCA1/2m and 2 who were somatic BRCA1/2m in 
SOLO1.

Demographic and baseline characteristics were generally well balanced between the olaparib and 
placebo treatment arms. Median age was 53 years in both arms. Ovarian cancer was the primary 
tumour in 85% of the patients. The most common histological type was serous (96%), endometrioid 
histology was reported in 2% of the patients. Most patients were ECOG performance status 0 (78%), 
there are no data in patients with performance status 2 to 4. Sixty-three percent (63%) of the patients 
had upfront debulking surgery and of these the majority (75%) had no macroscopic residual disease. 
Interval debulking surgery was performed in 35% of the patients and of these 82% had no 
macroscopic residual disease reported. Seven patients, all stage IV, had no cytoreductive surgery. All 
patients had received first-line platinum-based therapy. There was no evidence of disease at study 
entry (CR), defined by the investigator as no radiological evidence of disease and cancer antigen 125 
(CA-125) within normal range, in 73% and 77% of patients in the olaparib and placebo arms, 
respectively. PR, defined as the presence of any measurable or non-measurable lesions at baseline or 
elevated CA-125, was reported in 27% and 23% of patients in the olaparib and placebo arms, 
respectively. Ninety three percent (93%) of patients were randomised within 8 weeks of their last dose 
of platinum-based chemotherapy. Patients who had been treated with bevacizumab were excluded 
from the study, therefore there are no safety and efficacy data on olaparib patients who had previously 
received bevacizumab. There are very limited data in patients with a somatic BRCA mutation.

The primary endpoint was progression-free survival (PFS) defined as time from randomisation to 
progression determined by investigator assessment using modified Response Evaluation Criteria in 



30

Solid Tumors (RECIST) 1.1, or death. Secondary efficacy endpoints included time from 
randomisation to second progression or death (PFS2), overall survival (OS), time from randomisation 
to discontinuation of treatment or death (TDT), time from randomisation to first subsequent anti-
cancer therapy or death (TFST) and health related quality of life (HRQoL). Patients had tumour 
assessments at baseline and every 12 weeks for 3 years, and then every 24 weeks relative to date of 
randomisation, until objective radiological disease progression.

The study demonstrated a clinically relevant and statistically significant improvement in investigator 
assessed PFS for olaparib compared to placebo. The investigator assessment of PFS was supported 
with a blinded independent central radiological (BICR) review of PFS. At the time of PFS analysis, 
interim OS data were immature (21%), with HR 0.95 (95% CI 0.60, 1.53; p-value=0.9). Efficacy 
results are presented in Table 2 and Figures 1 and 2.

Table 2 Efficacy results for newly diagnosed patients with BRCA1/2m advanced ovarian cancer in 
SOLO1

Olaparib 300 mg bd Placeboc

PFS (51% maturity)a

Number of events: Total number of patients (%) 102:260 (39) 96:131 (73)

Median time (months) NR 13.8

HR (95% CI)b 0.30 (0.23-0.41)

P value (2-sided) p<0.0001

PFS2 (31% maturity) 

Number of events: Total number of patients (%) 69:260 (27) 52:131 (40)
Median time (months) NR 41.9

HR (95% CI) c 0.50 (0.35-0.72)
P value (2-sided) p=0.0002

TFST (49% maturity)

Number of events: Total number of patients (%) 99:260 (38) 94:131 (72)
Median time (months) 51.8 15.1

HR (95% CI) c 0.30 (0.22-0.40)
P value* (2-sided) p<0.0001

a Based on Kaplan-Meier estimates, the proportion of patients that were progression free at 24 and 36 months 
were 74% and 60% for olaparib versus 35% and 27% for placebo; the median follow-up time was 41 
months for both the olaparib and placebo arms.

b A value <1 favours olaparib. The analysis was performed using a Cox proportional hazards model 
including response to previous platinum chemotherapy (CR or PR) as a covariate.

c Of the 94 patients on the placebo arm who received subsequent therapy, 49 (52%) received a PARP 
inhibitor.

* Not controlled for multiplicity.
bd Twice daily; NR Not reached; CI Confidence interval; PFS Progression-free survival; PFS2 Time to second 

progression or death; OS Overall survival; TFST Time from randomisation to first subsequent anti-cancer 
therapy or death.



31

Figure 1 SOLO1: Kaplan-Meier plot of PFS in newly diagnosed patients with BRCA1/2m

advanced ovarian cancer (51% maturity - investigator assessment)

Figure 2 SOLO1: Kaplan-Meier plot of OS in newly diagnosed patients with BRCA1/2m
advanced ovarian cancer (21% maturity)



32

Consistent results were observed in the subgroups of patients by evidence of the disease at study entry. 
Patients with CR defined by the investigator had HR 0.34 (95% CI 0.24–0.47); median PFS not 
reached on olaparib vs 15.3 months on placebo. At 24 and 36 months, respectively, 68% and 45% 
patients remained in CR in the olaparib arm, and 34% and 22% of patients in the placebo arm. Patients 
with PR at study entry had PFS HR 0.31 (95% CI 0.18, 0.52; median PFS 30.9 months on olaparib vs 
8.4 months on placebo). Patients with PR at study entry either achieved CR (15% in olaparib arm and 
4% in the placebo arm at 24 months, remained in CR at 36 months) or had further PR/stable disease 
(43% in olaparib arm and 15% in the placebo arm at 24 months; 17% in olaparib arm and 15% in 
placebo arm at 36 months). The proportion of patients who progressed within 6 months of the last dose 
of platinum-based chemotherapy was 3.5% for olaparib and 8.4% for placebo.

Maintenance treatment of platinum-sensitive relapsed (PSR) ovarian cancer
SOLO2 Study
The safety and efficacy of olaparib as maintenance therapy were studied in a Phase III randomised, 
double-blind, placebo-controlled trial in patients with germline BRCA1/2-mutated PSR ovarian, 
fallopian tube or primary peritoneal cancer. The study compared the efficacy of Lynparza maintenance 
treatment (300 mg [2 x 150 mg tablets] twice daily) taken until progression with placebo treatment in 
295 patients with high-grade serous or endometrioid PSR ovarian cancer (2:1 randomisation: 196 
olaparib and 99 placebo) who were in response (CR or PR) following completion of 
platinum-containing chemotherapy. 

Patients who have received two or more platinum-containing regimens and whose disease had 
recurred >6 months after completion of penultimate platinum-based chemotherapy were enrolled. 
Patients could not have received prior olaparib or other PARP inhibitor treatment. Patients could have 
received prior bevacizumab, except in the regimen immediately prior to randomisation. 

All patients had evidence of gBRCA1/2m at baseline. Patients with BRCA1/2 mutations were identified 
either from germline testing in blood via a local test or by central testing at Myriad or from testing a 
tumour sample using a local test. Large rearrangements in the BRCA1/2 genes were detected in 4.7% 
(14/295) of the randomised patients.

Demographic and baseline characteristics were generally well balanced between the olaparib and 
placebo arms. Median age was 56 years in both arms. Ovarian cancer was the primary tumour in 
>80% of the patients. The most common histological type was serous (> 90%), endometrioid histology 
was reported in 6% of the patients. In the olaparib arm 55% of the patients had only 2 prior lines of 
treatment with 45% receiving 3 or more prior lines of treatment. In the placebo arm 61% of patients 
had received only 2 prior lines with 39% receiving 3 or more prior lines of treatment. Most patients 
were ECOG performance status 0 (81%), there are no data in patients with performance status 2 to 4. 
Platinum-free interval was >12 months in 60% and >6-12 months in 40% of the patients. Response to 
prior platinum chemotherapy was complete in 47% and partial in 53% of the patients. In the olaparib 
and placebo arms, 17% and 20% of patients had prior bevacizumab, respectively.

The primary endpoint was PFS determined by investigator assessment using RECIST 1.1. Secondary 
efficacy endpoints included PFS2; OS, TDT, TFST, TSST; and HRQoL.

The study met its primary objective demonstrating a statistically significant improvement in 
investigator assessed PFS for olaparib compared with placebo with a HR of 0.30 (95% CI 0.22-0.41; 
p<0.0001; median 19.1 months olaparib vs 5.5 months placebo). The investigator assessment of PFS 
was supported with a blinded independent central radiological review of PFS (HR 0.25; 95% CI 
0.18-0.35; p<0.0001; median 30.2 months for olaparib and 5.5 months placebo). At 2 years, 43% 
olaparib-treated patients remained progression free compared with only 15% placebo-treated patients.



33

A summary of the primary objective outcome for patients with gBRCA1/2m PSR ovarian cancer in 
SOLO2 is presented in Table 3 and Figure 3.

Table 3 Summary of primary objective outcome for patients with gBRCA1/2m PSR ovarian cancer in 
SOLO2

Olaparib 300 mg tablet bd Placebo

PFS (63% maturity)

Number of events: Total number of 
patients (%)

107:196 (55) 80:99 (81)

Median time (months) (95% CI) 19.1 (16.3-25.7) 5.5 (5.2-5.8)
HR (95% CI) a 0.30 (0.22-0.41)
P value (2-sided) p<0.0001

a HR= Hazard Ratio. A value <1 favours olaparib. The analysis was performed using a Cox proportional hazard model 
including response to previous platinum chemotherapy (CR or PR), and time to disease progression (>6-12 months 
and >12 months) in the penultimate platinum-based chemotherapy as covariates.

bd Twice daily; PFS progression-free survival; CI confidence interval 

Figure 3 SOLO2: Kaplan-Meier plot of PFS in patients with gBRCA1/2m PSR ovarian cancer 

(63% maturity - investigator assessment)

bd Twice daily; PFS Progression free survival

The secondary endpoints TFST and PFS2 demonstrated a persistent and statistically significant 
improvement for olaparib compared with placebo (Table 4).

P
ro

po
rt

io
n 

of
 p

at
ie

nt
s 

ev
en

t 
fr

ee

Time from randomisation (months)

- - - - - - - - - Placebo bd --------------Olaparib 300 mg bd

Number of patients at risk:

196 182 156 134 118 104 89 82 32 29 3 2 0 Olaparib 300 mg bd

99 70 37 22 18 17 14 12 7 6 0 0 0 Placebo bd



34

Table 4 Summary of key secondary objective outcomes for patients with gBRCA1/2m PSR ovarian 
cancer in SOLO2

Olaparib 300 mg tablet bd Placebo

TFST (58% maturity)

Number of events: Total number of 
patients (%)

92:196 (47) 79:99 (80)

Median time (months) (95% CI) 27.9 (22.6-NR) 7.1 (6.3-8.3)
HR (95% CI) a 0.28 (0.21-0.38)
P value* (2-sided) p<0.0001

PFS2 (40% maturity)

Number of events: Total number of 
patients (%)

70:196 (36) 49:99 (50) 

Median time (months) (95% CI) NR (24.1-NR) 18.4 (15.4-22.8)
HR (95% CI) a 0.50 (0.34-0.72) 
P value (2-sided) p=0.0002

* Not controlled for multiplicity.
a HR= Hazard Ratio. A value <1 favours olaparib. The analysis was performed using a Cox proportional hazard model 

including response to previous platinum chemotherapy (CR or PR), and time to disease progression (>6-12 months 
and >12 months) in the penultimate platinum-based chemotherapy as covariates.

bd Twice daily; NR not reached; CI confidence interval; PFS2 time from randomisation to second progression or death; 
TFST Time from randomisation to start of first subsequent therapy or death.

Among the patients entering the trial with measurable disease (target lesions at baseline), an objective 
response rate of 41% was achieved in the Lynparza arm versus 17% on placebo. Of patients treated 
with Lynparza, who entered the study with evidence of disease (target or non-target lesions at 
baseline), 15.0% experienced complete response compared with 9.1% of patients on placebo.

At the time of the analysis of PFS the median duration of treatment was 19.4 months for olaparib and 
5.6 months for placebo. The majority of patients remained on the 300 mg bd starting dose of olaparib. 
The incidence of dose interruptions, reductions, discontinuations due to an adverse event was 45.1%,
25.1% and 10.8%, respectively. Dose interruptions occurred most frequently in the first 3 months and 
dose reductions in the first 3-6 months of treatment. The most frequent adverse reactions leading to 
dose interruption or dose reduction were anaemia, nausea and vomiting.

Patient-reported outcome (PRO) data indicate no difference for the olaparib-treated patients as 
compared to placebo as assessed by the change from baseline in the TOI of the FACT-O.

Study 19 (D0810C00019) 

The safety and efficacy of olaparib as a maintenance therapy in the treatment of PSR ovarian, 
including fallopian tube or primary peritoneal cancer patients, following treatment with two or more 
platinum-containing regimens, were studied in a large Phase II randomised, double-blind, 
placebo-controlled trial (Study 19). The study compared the efficacy of Lynparza capsule maintenance 
treatment (400 mg [8 x 50 mg capsules] twice daily) taken until progression with placebo treatment in 
265 (136 olaparib and 129 placebo) PSR high grade serous ovarian cancer patients who were in 
response (CR or PR) following completion of platinum-containing chemotherapy. The primary 
endpoint was PFS based on investigator assessment using RECIST 1.0. Secondary efficacy endpoints 
included OS, disease control rate (DCR) defined as confirmed CR/PR + SD (stable disease), HRQoL 
and disease related symptoms. Exploratory analyses of TFST and TSST were also performed.

Patients whose disease had recurred >6 months after completion of penultimate platinum-based 
chemotherapy were enrolled. Enrolment did not require evidence of BRCA1/2 mutation (BRCA
mutation status for some patients was determined retrospectively). Patients could not have received 
prior olaparib or other PARP inhibitor treatment. Patients could have received prior bevacizumab, 
except in the regimen immediately prior to randomisation. Retreatment with olaparib was not 
permitted following progression on olaparib.



35

Patients with BRCA1/2 mutations were identified either from germline testing in blood via a local test 
or by central testing at Myriad or from testing a tumour sample using a test performed by Foundation 
Medicine. Large rearrangements in the BRCA1/2 genes were detected in 7.4% (10/136) of the 
randomised patients.

Demographic and baseline characteristics were generally well balanced between the olaparib and 
placebo arms. Median age was 59 years in both arms. Ovarian cancer was the primary tumour in 86% 
of the patients. In the olaparib arm 44% of the patients had only 2 prior lines of treatment with 56% 
receiving 3 or more prior lines of treatment. In the placebo arm 49% of patients had received only 2 
prior lines with 51% receiving 3 or more prior lines of treatment. Most patients were ECOG 
performance status 0 (77%), there are no data in patients with performance status 2 to 4. Platinum-free 
interval was > 12 months in 60% and 6-12 months in 40% of the patients. Response to prior platinum 
chemotherapy was complete in 45% and partial in 55% of the patients. In the olaparib and placebo 
arms, 6% and 5% of patients had prior bevacizumab, respectively.

The study met its primary objective demonstrating a statistically significant improvement in PFS for 
olaparib compared with placebo in the overall population with a HR of 0.35 (95% CI 0.25-0.49; 
p<0.00001; median 8.4 months olaparib vs 4.8 months placebo). At the final OS analysis (data cut off 
[DCO] 9 May 2016) at 79% maturity, the hazard ratio comparing olaparib with placebo was 0.73 
(95% CI 0.55-0.95; p=0.02138 [did not meet pre-specified significance level of <0.0095]; median 
29.8 months olaparib versus 27.8 months placebo). In the olaparib-treated group, 23.5% (n=32/136) of 
patients remained on treatment for ≥2 years as compared with 3.9% (n=5/128) of the patients on 
placebo. Although patient numbers were limited, 13.2% (n=18/136) of the patients in the
olaparib-treated group remained on treatment for ≥5 years as compared with 0.8% (n=1/128) in the 
placebo group.

Preplanned subgroup analysis identified patients with BRCA1/2-mutated ovarian cancer (n=136, 
51.3%; including 20 patients identified with a somatic tumour BRCA1/2 mutation) as the subgroup 
that derived the greatest clinical benefit from olaparib maintenance monotherapy. A benefit was also 

observed in patients with BRCA1/2 wild-type/variants of uncertain significance (BRCA1/2 wt/VUS), 

although of a lesser magnitude. There was no strategy for multiple testing in place for the sub-group 

analyses.

A summary of the primary objective outcome for patients with BRCA1/2-mutated and BRCA1/2

wt/VUS PSR ovarian cancer in Study 19 is presented in Table 4 and for all patients in Study 19 in 

Table 5 and Figure 4.



36

Table 5 Summary of primary objective outcome for all patients and patients with BRCA1/2-mutated 
and BRCA1/2 wt/VUS PSR ovarian cancer in Study 19

All patientsa BRCA1/2-mutated BRCA1/2 wt/VUS

Olaparib 
400 mg 
capsule bd

Placebo Olaparib 

400 mg 
capsule bd

Placebo Olaparib 

400 mg 

capsule bd

Placebo

PFS – DCO 30 June 2010

Number of 
events: Total 
number of 
patients (%)

60:136 (44) 94:129 (73) 26:74 (35) 46:62 (74) 32:57 (56) 44:61 (72)

Median time 
(months) (95% 
CI)

8.4

(7.4-11.5)

4.8

(4.0-5.5)

11.2 

(8.3-NR)

4.3 

(3.0-5.4)

7.4

(5.5-10.3)

5.5

(3.7-5.6)

HR (95% CI) b 0.35 (0.25-0.49) 0.18 (0.10–0.31) 0.54 (0.34-0.85)

P value 
(2-sided) 

p<0.00001 p<0.00001 p=0.00745

a All patients comprises of the following subgroups: BRCA1/2-mutated, BRCA1/2 wt/VUS and BRCA1/2 status 
unknown (11 patients with status unknown, not shown as a separate subgroup in table). 

b HR= Hazard Ratio. A value <1 favours olaparib. The analysis was performed using a Cox proportional hazards 
model with factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.

bd Twice daily; PFS progression-free survival; DCO data cut off; CI confidence interval; NR not reached.

Figure 4 Study 19: Kaplan-Meier plot of PFS in the FAS (58% maturity - investigator 
assessment) DCO 30 June 2010

Time from randomisation (months)

--------------Placebo bd - - - - - - - - - Olaparib 400 mg bd

Number of patients at risk:

136 106 53 24 7 0 Olaparib 400 mg bd

129 72 24 7 1 0 Placebo 

bd Twice daily; DCO Data cut-off; FAS Full analysis set; PFS progression-free survival

A summary of key secondary objective outcomes for patients with BRCA1/2-mutated and BRCA1/2

wt/VUS PSR ovarian cancer in Study 19 is presented in Table 6 and for all patients in Study 19 in 

Table 6 and Figure 5.

P
ro

po
rt

io
n 

of
 p

at
ie

nt
s 

ev
en

t 
fr

ee



37

Table 6 Summary of key secondary objective outcomes for all patients and patients with 
BRCA1/2-mutated and BRCA1/2 wt/VUS PSR ovarian cancer in Study 19

All patientsa BRCA1/2-mutated BRCA1/2 wt/VUS

Olaparib 
400 mg 
capsule bd

Placebo Olaparib 

400 mg 
capsule bd

Placebo Olaparib 

400 mg 

capsule bd

Placebo

OS - DCO 09 May 2016

Number of 
events: Total 
number of 
patients (%)

98:136 (72) 112:129 
(87)

49:74 (66) 50:62 (81) c 45:57 (79) 57:61 (93)

Median time 
(months) 
(95% CI)

29.8

(26.9-35.7)

27.8

(24.9-33.7)

34.9 

(29.2-54.6)

30.2 

(23.1-40.7)

24.5

(19.8-35.0)

26.6

(23.1-32.5)

HR (95% CI)b 0.73 (0.55–0.95) 0.62 (0.42–0.93) 0.84 (0.57-1.25)

P value*

(2-sided)
p=0.02138 p=0.02140 p=0.39749

TFST – DCO 09 May 2016

Number of 
events: Total 
number of 
patients (%)

106:136 
(78)

124:128 
(97)

55:74 (74) 59:62 (95) 47:57 (83) 60:61 (98)

Median time 
(months) 
(95% CI)

13.3

(11.3-15.7)

6.7

(5.7-8.2)

15.6

(11.9-28.2)

6.2

(5.3-9.2)

12.9

(7.8-15.3)

6.9

(5.7-9.3)

HR (95% CI)b 0.39 (0.30–0.52) 0.33 (0.22-0.49) 0.45 (0.30-0.66)

P value*

(2-sided) 
p<0.00001 p<0.00001 p=0.00006

*            There was no strategy for multiple testing in place for the sub-group analyses or for the all patients TFST.
a All patients comprises of the following subgroups: BRCA1/2-mutated, BRCA1/2 wt/VUS and BRCA1/2 status unknown 

(11 patients with status unknown, not shown as a separate subgroup in table). 
b HR= Hazard Ratio. A value <1 favours olaparib. The analysis was performed using a Cox proportional hazards model 

with factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
c Approximately a quarter of placebo-treated patients in the BRCA-mutated subgroup (14/62; 22.6%) received a 

subsequent PARP inhibitor.
bd Twice daily; OS Overall survival; DCO data cut off; CI confidence interval; TFST time from randomisation to start of 

first subsequent therapy or death.



38

Figure 5 Study 19: Kaplan Meier plot of OS in the FAS (79% maturity) DCO 09 May 2016

Time from randomisation (months)

--------------Placebo bd - - - - - - - - - Olaparib 400 mg bd

Number of patients at risk:

       

bd Twice daily; DCO Data cut off; FAS Full analysis set; OS Overall survival

At the time of the analysis of PFS the median duration of treatment was 8 months for olaparib and 4 
months for placebo. The majority of patients remained on the 400 mg bd starting dose of olaparib. The 
incidence of dose interruptions, reductions and discontinuations due to an adverse event was 34.6%, 
25.7% and 5.9%, respectively. Dose interruptions and reductions occurred most frequently in the first 
3 months of treatment. The most frequent adverse reactions leading to dose interruption or dose 
reduction were nausea, anaemia, vomiting, neutropenia and fatigue. The incidence of anaemia adverse 
reactions was 22.8% (CTCAE grade ≥3 7.4%).

Patient-reported outcome (PRO) data indicate no difference for the olaparib-treated patients as 
compared to placebo as measured by improvement and worsening rates in the TOI and FACT-O total.

gBRCA1/2-mutated HER2-negative metastatic breast cancer
OlympiAD (Study D0819C00003) 
The safety and efficacy of olaparib in patients with gBRCA1/2-mutations who had HER2-negative 
metastatic breast cancer were studied in a Phase III randomised, open-label, controlled trial 
(OlympiAD). In this study 302 patients with a documented deleterious or suspected deleterious 
gBRCA mutation were randomised 2:1 to receive either Lynparza (300 mg [2 x 150 mg tablets] twice 
daily) or physician’s choice of chemotherapy (capecitabine 42%, eribulin 35%, or vinorelbine 17%)
until progression or unacceptable toxicity. Patients with BRCA1/2 mutations were identified from 
germline testing in blood via a local test or by central testing at Myriad. Patients were stratified based 
on: receipt of prior chemotherapy regimens for metastatic breast cancer (yes/no), hormone receptor
(HR) positive vs triple negative (TNBC), prior platinum treatment for breast cancer (yes/no). The 
primary endpoint was PFS assessed by blinded independent central review (BICR) using RECIST 1.1. 
Secondary endpoints included PFS2, OS, objective response rate (ORR) and HRQoL.

Patients must have received treatment with an anthracycline unless contraindicated and a taxane in 
either a (neo)adjuvant or metastatic setting. Patients with HR+ (ER and/or PgR positive) tumours must 
have received and progressed on at least one endocrine therapy (adjuvant or metastatic) or had disease 
that the treating physician believed to be inappropriate for endocrine therapy. Prior therapy with 
platinum was allowed in the metastatic setting provided there had been no evidence of disease 

Olaparib 400 mg bd

Placebo

P
ro

po
rt

io
n 

of
 p

at
ie

nt
s 

al
iv

e



39

progression during platinum treatment and in the (neo)adjuvant setting provided the last dose was 
received at least 12 months prior to randomisation. No previous treatment with a PARP inhibitor, 
including olaparib, was permitted.

Demographic and baseline characteristics were generally well balanced between the olaparib and 
comparator arms (see Table 7).

Table 7 Patient demographic and baseline characteristics in OlympiAD

Olaparib 300 mg bd

n=205

Chemotherapy

n=97

Age - year (median) 44 45

Gender (%)

Female 200 (98) 95 (98)

Male 5 (2) 2 (2)

Race (%)

White 134 (65) 63 (65)

Asian 66 (32) 28 (29)

Other 5 (2) 6 (6)

ECOG performance status (%)

0 148 (72) 62 (64)

1 57 (28) 35 (36)

Overall disease classification

Metastatic 205 (100) 97 (100)

Locally advanced 0 0 

New metastatic breast cancer (%) 26 (13) 12 (12)

Hormone receptor status (%)

HR+ 103 (50) 49 (51)

TNBC 102 (50) 48 (49)

gBRCA mutation type (%)

gBRCA1 117 (57) 51 (53)

gBRCA2 84 (41) 46 (47)

gBRCA1 and gBRCA2 4 (2) 0

≥2 Metastatic sites (%) 159 (78) 72 (74)

Location of the metastasis (%)

Bone only 16 (8) 6 (6)

Other 189 (92) 91 (94)

Measurable disease by BICR (%) 167 (81) 66 (68)

Progressive disease at time of 
randomization (%)

159 (78) 73 (75)

Tumour grade at diagnosis

Well differentiated (G1) 5 (2) 2 (2)

Moderately differentiated (G2) 52 (25) 23 (24)

Poorly differentiated (G3) 108 (53) 55 (57)

Undifferentiated (G4) 4 (2) 0

Unassessable (GX) 27 (13) 15 (16)



40

Missing 9 (4) 2 (2)

Number of prior lines of chemotherapy for metastatic breast cancer (%)

0 68 (33) 31 (32)

1 80 (39) 42 (43)

2 57 (28) 24 (25)

Previous platinum-based therapy 
(%)

55 (27) 21 (22)

in (neo)adjuvant setting only 12 (6) 6 (6)

metastatic setting only 40 (20) 14 (14)

in (neo)adjuvant and metastatic setting 3 (1) 1 (1)

Previous anthracycline treatment

in (neo) adjuvant setting 169 (82) 76 (78)

metastatic setting 41 (20) 16 (17)

Previous taxane treatment

in (neo)adjuvant setting 146 (71) 66 (68)

metastatic setting 107 (52) 41 (42)

Previous anthracycline and taxane 
treatment

204 (99.5) 96 (99)

As subsequent therapy, 0.5% and 8% of patients received a PARP inhibitor in the treatment and 
comparator arms, respectively; 29% and 42% of patients, respectively, received subsequent platinum 
therapy.

A statistically significant improvement in PFS, the primary efficacy outcome, was demonstrated for 
olaparib-treated patients compared with those in the comparator arm (see Table 8 and Figure 6). 

Table 8 Summary of key efficacy findings for patients with gBRCA1/2-mutated HER2-
negative metastatic breast cancer in OlympiAD

Olaparib 300 mg bd Chemotherapy

PFS (77% maturity) – DCO 09 December 2016

Number of events: Total number of 
patients (%)

163:205 (80) 71:97 (73)

Median time (months) (95% CI) 7.0 (5.7-8.3) 4.2 (2.8-4.3)

HR (95% CI) 0.58 (0.43-0.80)

P value (2-sided)a p=0.0009

PFS2 (65% maturity) - DCO 25 September 2017b

Number of events: Total number of 
patients (%)

130:205 (63) 65:97 (67)

Median time (months) (95% CI) 12.8 (10.9-14.3) 9.4 (7.4-10.3)

HR (95% CI) 0.55 (0.39-0.77)

P value (2-sided)a p=0.0005

OS (64% maturity) – DCO 25 September 2017

Number of events: Total number of 
patients (%)

130:205 (63) 62:97 (64)

Median time (months) (95% CI) 19.3 (17.2-21.6)c 17.1 (13.9-21.9)

HR (95% CI) 0.90 (0.66-1.23)

P value (2-sided)a p=0.5131



41

Confirmed ORR – DCO 09 December 2016

Number of objective responders: Total 
number of patients with measurable 
disease (%)

87: 167 (52)d 15:66 (23)

95% CI 44.2-59.9 13.3-34.7

DOR – DCO 09 December 2016

Median, months (95% CI) 6.9 (4.2, 10.2) 7.9 (4.5, 12.2)
a Based on stratified log-rank test.
b Post-hoc analysis.
c The median follow-up time in censored patients was 25.3 months for olaparib versus 26.3 months for comparator.
d Confirmed responses (by BICR) were defined as a recorded response of either CR/PR, confirmed by repeat imaging not 

less than 4 weeks after the visit when the response was first observed. In the olaparib arm 8% with measurable disease 
had a complete response versus 1.5% of patients in the comparator arm; 74/167 (44%) of patients in the olaparib arm 
had a partial response versus 14/66 (21%) of patients in the chemotherapy arm. In the TNBC patient subgroup the 
confirmed ORR was 48% (41/86) in the olaparib arm and 12% (4/33) in the comparator arm. In the HR+ patient 
subgroup the confirmed ORR was 57% (46/81) in the olaparib arm and 33% (11/33) in the comparator arm.

bd Twice daily; CI Confidence interval; DOR Duration of response; DCO Data cut off; HR Hazard ratio; HR+ Hormone 
receptor positive, ORR Objective response rate; OS overall survival; PFS progression-free survival; PFS2 Time to 
second progression or death, TNBC triple negative breast cancer.

Figure 6 OlympiAD: Kaplan-Meier plot of BICR PFS in patients with gBRCA1/2-mutated
HER2-negative metastatic breast cancer (77% maturity) DCO 09 December 2016

Consistent results were observed in all predefined patient subgroups (see Figure 7). Subgroup analysis 
indicated PFS benefit of olaparib versus comparator in TNBC (HR 0.43; 95% CI: 0.29-0.63, n=152) 
and HR+ (HR 0.82; 95% CI: 0.55-1.26, n=150) patient subgroups.

P
ro

ba
bi

li
ty

 o
f 

pr
og

re
ss

io
n 

fr
ee

 s
ur

vi
va

l 

Chemotherapy (N = 97)
Olaparib 300 mg twice daily (N = 205)

Time from randomisation (months)

Number of patients at risk
Olaparib 300 mg twice daily tablet

Chemotherapy



42

Figure 7 PFS (BICR), Forest plot, by prespecified subgroup

In a post-hoc analysis of the subgroup of patients that had not progressed on chemotherapy other than 
platinum, the median PFS in the olaparib arm (n=22) was 8.3 months (95% CI 3.1-16.7) and 2.8 
months (95% CI 1.4-4.2) in the chemotherapy arm (n=16) with a HR of 0.54 (95% CI 0.24-1.23).
However, the number of patients is too limited to make meaningful conclusions on the efficacy in this 
subgroup. 

Seven male patients were randomised (5 olaparib and 2 comparator). At the time of the PFS analysis, 
1 patient had a confirmed partial response with a duration of response of 9.7 months in the olaparib 
arm. There were no confirmed responses in the comparator arm.



43

Figure 8 OlympiAD: Kaplan-Meier plot of OS in patients with gBRCA1/2-mutated HER2-negative 
metastatic breast cancer (64% maturity) DCO 25 September 2017

OS analysis in patients with no prior chemotherapy for metastatic breast cancer indicated benefit in 
these patients with a HR of 0.45 (95% CI 0.27-0.77), while for further lines of therapy HR exceeded 1.

Maintenance following first-line treatment of germline BRCA-mutated metastatic adenocarcinoma of 
the pancreas:
POLO Study

The safety and efficacy of olaparib as maintenance therapy were studied in a randomised (3:2), 
double-blind, placebo-controlled, multicentre trial in 154 patients with germline BRCA1/2 mutations 
who had metastatic adenocarcinoma of the pancreas. Patients received either Lynparza 300 mg (2 x 
150 mg tablets) twice daily (n=92) or placebo (n=62) until radiological disease progression or 
unacceptable toxicity. Patients should have not progressed during first-line platinum-based 
chemotherapy and should have received a minimum of 16 weeks of continuous platinum treatment,
which could be discontinued at any time thereafter for unacceptable toxicity while the remaining
agents continued according to the planned regimen or unacceptable toxicity for other component(s). 
Patients who could tolerate complete platinum-containing chemotherapy regimen until progression 
have not been considered for this study. The maintenance therapy was started 4 to 8 weeks after the 
last dose of first-line chemotherapy component(s) in the absence of progression and if all toxicities
from previous anti-cancer therapy had been resolved to CTCAE grade 1, except for alopecia, grade 3 
peripheral neuropathy and Hgb ≥ 9 g/dL.

Thirty-one percent (31%) of patients with germline BRCA1/2 mutations were identified from prior 
local testing results and 69% of patients by central testing. In the olaparib arm, 32% of patients carried 
a germline BRCA1 mutation, 64% a germline BRCA2 mutation and 1% carried both germline BRCA1
and germline BRCA2 mutations. In the placebo arm, 26% of patients carried a germline BRCA1
mutation, 73% a germline BRCA2 mutation and no patients carried both germline BRCA1 and 



44

germline BRCA2 mutations. The BRCAm status of all patients identified using prior local testing 
results was confirmed, where sent, by central testing. Ninety-eight percent (98%) of patients carried a 
deleterious mutation and 2% carried a suspected deleterious mutation. Large rearrangements in the 
BRCA1/2 genes were detected in 5.2 % (8/154) of the randomised patients.

Demographic and baseline characteristics were generally well balanced between the olaparib and 
placebo arms. Median age was 57 years in both arms; 30% of patients in the olaparib arm were ≥ 65 
years compared to 20% in the placebo arm. Fifty-eight per-cent (58%) of patients in the olaparib arm 
and 50% of patients in the placebo arm were male. In the olaparib arm 89% of patients were White 
and 11% were non-White; in the placebo arm 95% of patients were White and 5% were non-White. 
Most patients were ECOG performance status 0 (71% in the olaparib arm and 61% in the placebo 
arm). Overall, the sites of metastasis prior to chemotherapy were liver 72%, lung 10% and other sites 
50%. The median time from original diagnosis to randomisation across both arms was 6.9 months 
(range 3.6 to 38.4 months).

Overall, 75% of patients received FOLFIRINOX with a median of 9 cycles (range 4-61), 8% received 
FOLFOX or XELOX, 4% received GEMOX, and 3% received gemcitabine plus cisplatin; the 
remaining 10% of patients received other chemotherapy regimens. Duration of the first-line 
chemotherapy for metastatic disease was 4 to 6 months, >6 to <12 months and ≥12 months, 
respectively, in 77%, 19% and 4% of patients in the olaparib arm and in 80%, 17% and 3% in the 
placebo arm, with around 1 month from the last dose of the first-line chemotherapy component(s) to 
the start of study treatment in both arms. As best response on first-line chemotherapy, 7% of olaparib 
patients and 5% of placebo patients had a complete response, 44% of olaparib patients and 44% of 
placebo patients had a partial response and 49% of olaparib and 50% of placebo patients had stable 
disease. At randomisation, measurable disease was reported in 85% and 84% of patients in the 
olaparib or placebo arms, respectively. The median time from initiation of the first-line platinum-
based chemotherapy to randomisation was 5.7 months (range 3.4 to 33.4 months).

At DCO, 33% of patients in the olaparib arm and 13% on the placebo arm remained on study 
treatment. Forty-nine percent of patients (49%) in the olaparib arm and 74% in the placebo arm 
received subsequent therapy. Forty-two percent (42%) of patients in the olaparib arm and 55% in the 
placebo arm received platinum as subsequent therapy. One percent (1%) of patients in the olaparib 
arm and 15% in the placebo arm received PARP inhibitor as subsequent therapy. Of the 33 (36%) and 
28 (45%) of patients who received a first subsequent platinum-containing therapy, in the olaparib and 
placebo arms, stable disease was reported in 8 vs 6 patients, whereas 1 vs 2 patients had responses, 
respectively.

The primary endpoint was progression-free survival (PFS), defined as time from randomisation to 

progression determined by BICR using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

modified to assess patients with no evidence of disease, or death. Secondary efficacy endpoints 

included overall survival (OS), time from randomisation to second progression or death (PFS2), time 

from randomisation to first subsequent anti-cancer therapy or death (TFST), objective response rate 

(ORR), duration of response (DoR), response rate, time to response and health related quality of life 

(HRQoL). 

The study demonstrated a statistically significant improvement in PFS for olaparib compared to 

placebo (Table 9). The BICR assessment of PFS was consistent with an investigator assessment.

At the interim analysis of OS (46% maturity) the HR was 0.91 (95% CI 0.56 – 1.46; p=0.6833; median 
18.9 months for olaparib vs 18.1 months for placebo) which did not reach statistical significance. The 
HR for PFS2 (47% maturity, not controlled for multiplicity) was 0.76 (95% CI 0.46 – 1.23; p=0.2597; 
median 13.2 months for olaparib vs 9.2 months for placebo).



45

Table 9 Efficacy results for patients with gBRCAm metastatic adenocarcinoma of the 

pancreas in POLO (BICR, DCO 15 January 2019)

Olaparib 300 mg bd Placebo

PFS (68% maturity)a,b

Number of events: Total number of patients (%) 60:92 (65) 44:62 (71)
Median time, months (95% CI) 7.4 (4.14-11.01) 3.8 (3.52-4.86)
HR (95% CI)c,d 0.53 (0.35-0.82)
P value (2-sided) p=0.0038

ORR
Number of objective responders: total number of 
patients with measurable disease at baseline (%)

18:78 (23.1) 6:52 (11.5)

Complete response (%) 2 (2.6) 0
Partial response (%) 16 (20.5) 6 (11.5)

DoR
Median time (months) (95% CI) 24.9 (14.75-NC) 3.7 (2.10-NC)

a Based on Kaplan–Meier estimates, the proportion of patients that were alive and progression-free at 12 and 24 months 
were 34% and 22% for olaparib vs 15% and 10% for placebo.

b For PFS, the median follow-up time for censored patients was 9.1 months in the olaparib arm and 3.8 months in the 
placebo arm. For OS, the median follow-up time for censored patients was 13.4 months in the olaparib arm and 12.5 
months in the placebo arm.

c A value <1 favours olaparib. 
d The analysis was performed using a log-rank test.
bd Twice daily; CI Confidence interval; HR Hazard Ratio; NC Not calculable; ORR Objective Response Rate; PFS 

Progression-free survival.

Figure 9 POLO: Kaplan-Meier plot of PFS for patients with gBRCAm metastatic 

adenocarcinoma of the pancreas (68% maturity – BICR, DCO 15 January 2019)

___   Olaparib 300 mg twice daily tablet

_ _ _ Placebo twice daily tablet

P
ro

ba
bi

li
ty

 o
f 

pr
og

re
ss

io
n

-f
re

e 
su

rv
iv

al

Time from randomisation (months)Number of patients at risk:

Olaparib 300 mg twice daily tablet

Placebo twice daily tablet



46

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with 
Lynparza in all subsets of the paediatric population, in ovarian carcinoma (excluding 
rhabdomyosarcoma and germ cell tumours) (see section 4.2 for information on paediatric use). 

5.2 Pharmacokinetic properties

The pharmacokinetics of olaparib at the 300 mg tablet dose are characterised by an apparent plasma 
clearance of ~7 L/h, an apparent volume of distribution of ~158 L and a terminal half-life of 15 hours. 
On multiple dosing, an AUC accumulation ratio of 1.8 was observed and PK appeared to be 
time-dependent to a small extent.

Absorption
Following oral administration of olaparib via the tablet formulation (2 x 150 mg), absorption is rapid 
with median peak plasma concentrations typically achieved 1.5 hours after dosing.

Co-administration with food slowed the rate (tmax delayed by 2.5 hours and Cmax reduced by 
approximately 21%) but did not significantly affect the extent of absorption of olaparib (AUC 
increased 8%). Consequently, Lynparza may be taken without regard to food (see section 4.2).

Distribution
The in vitro plasma protein binding is approximately 82% at 10 µg/mL which is approximately Cmax.

In vitro, human plasma protein binding of olaparib was dose-dependent; the fraction bound was 
approximately 91% at 1 µg/mL, reducing to 82% at 10 µg/mL and to 70% at 40 µg/mL. In solutions of 
purified proteins, the olaparib fraction bound to albumin was approximately 56%, which was 
independent of olaparib concentrations. Using the same assay, the fraction bound to alpha-1 acid 
glycoprotein was 29% at 10 µg/mL with a trend of decreased binding at higher concentrations.

Biotransformation
In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of 
olaparib (see section 4.5).

Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the 
majority of the circulating radioactivity in plasma (70%) and was the major component found in both 
urine and faeces (15% and 6% of the dose, respectively). The metabolism of olaparib is extensive. The 
majority of the metabolism was attributable to oxidation reactions with a number of the components 
produced undergoing subsequent glucuronide or sulfate conjugation. Up to 20, 37 and 20 metabolites 
were detected in plasma, urine and faeces, respectively, the majority of them representing < 1% of the 
dosed material. A ring-opened piperazin-3-ol moiety, and two mono-oxygenated metabolites (each 
~10%) were the major circulating components, with one of the mono-oxygenated metabolites also 
being the major metabolite in the excreta (6% and 5% of the urinary and faecal radioactivity,
respectively). 

In vitro, olaparib produced little/no inhibition of UGT1A4, UGT1A9, UGT2B7, or CYPs 1A2, 2A6, 
2B6, 2C8, 2C9, 2C19, 2D6 or 2E1 and is not expected to be a clinically significant time dependent 
inhibitor of any of these CYP enzymes. Olaparib inhibited UGT1A1 in vitro, however, PBPK 
simulations suggest this is not of clinical importance. In vitro, olaparib is a substrate of the efflux 
transporter P-gp, however, this is unlikely to be of clinical significance (see section 4.5).

In vitro, data also show that olaparib is not a substrate for OATP1B1, OATP1B3, OCT1, BCRP or 
MRP2 and is not an inhibitor of OATP1B3, OAT1 or MRP2.



47

Elimination
Following a single dose of 14C-olaparib, ~86% of the dosed radioactivity was recovered within a 7-day 
collection period, ~44% via the urine and ~42% via the faeces. Majority of the material was excreted 
as metabolites. 

Special populations
In population based PK analyses, patient age, gender, bodyweight or race (including White and 
Japanese patients) were not significant covariates.

Renal impairment
In patients with mild renal impairment (creatinine clearance 51 to 80 ml/min), AUC increased by 24% 
and Cmax by 15% compared with patients with normal renal function. No Lynparza dose adjustment is 
required for patients with mild renal impairment.

In patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min), AUC increased by 
44% and Cmax by 26% compared with patients with normal renal function. Lynparza dose adjustment 
is recommended for patients with moderate renal impairment (see section 4.2).

There are no data in patients with severe renal impairment or end-stage renal disease (creatinine 
clearance <30 ml/min).

Hepatic impairment
In patients with mild hepatic impairment (Child-Pugh classification A), AUC increased by 15% and 
Cmax by 13% and in patients with moderate hepatic impairment (Child-Pugh classification B), AUC 
increased by 8% and Cmax decreased by 13% compared with patients with normal hepatic function. No 
Lynparza dose adjustment is required for patients with mild or moderate hepatic impairment (see 
section 4.2). There are no data in patients with severe hepatic impairment (Child-Pugh classification 
C).

Paediatric population
No studies have been conducted to investigate the pharmacokinetics of olaparib in paediatric patients.

5.3 Preclinical safety data

Genotoxicity
Olaparib showed no mutagenic potential, but was clastogenic in mammalian cells in vitro. When 
dosed orally to rats, olaparib induced micronuclei in bone marrow. This clastogenicity is consistent 
with the known pharmacology of olaparib and indicates potential for genotoxicity in man.

Repeat-dose toxicity
In repeat-dose toxicity studies of up to 6 months duration in rats and dogs, daily oral doses of olaparib 
were well-tolerated. The major primary target organ for toxicity in both species was the bone marrow, 
with associated changes in peripheral haematology parameters. These changes were reversible within 
4 weeks of cessation of dosing. In rats, minimal degenerative effects on gastrointestinal tract were also 
noted. These findings occurred at exposures below those seen clinically. Studies using human bone 
marrow cells also showed that direct exposure to olaparib can result in toxicity to bone marrow cells in 
ex vivo assays.

Reproductive toxicology
In a female fertility study where rats were dosed until implantation, although extended oestrus was 
observed in some animals, mating performance and pregnancy rate was not affected. However, there 
was a slight reduction in embryofoetal survival.

In rat embryofoetal development studies, and at dose levels that did not induce significant maternal 
toxicity, olaparib caused reduced embryofoetal survival, reduced foetal weight and foetal 



48

developmental abnormalities, including major eye malformations (e.g. anophthalmia, 
microphthalmia), vertebral/rib malformation and visceral and skeletal abnormalities. 

Carcinogenicity
Carcinogenicity studies have not been conducted with olaparib.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Copovidone
Silica, colloidal anhydrous
Mannitol
Sodium stearyl fumarate

Tablet coating
Hypromellose
Macrogol 400
Titanium dioxide (E171)
Iron oxide yellow (E172)
Iron oxide black (E172) (150 mg tablets only)

6.2 Incompatibilities

Not applicable. 

6.3 Shelf life

4 years.

6.4 Special precautions for storage

Store in the original package in order to protect from moisture.

This medicinal product does not require any special temperature storage conditions.

6.5 Nature and contents of container

Alu/Alu non-perforated blister containing 8 film-coated tablets.

Pack sizes:
56 film-coated tablets (7 blisters).
Multipack containing 112 (2 packs of 56) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.



49

7. MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/959/002
EU/1/14/959/003
EU/1/14/959/004
EU/1/14/959/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16 December 2014
Date of last renewal: 1 October 2019

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu.

http://www.ema.europa.eu/


50

ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT



51

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

AstraZeneca AB
Gärtunavägen
SE-151 85 Södertälje
Sweden

AstraZeneca UK Limited
Silk Road Business Park
Macclesfield
Cheshire
SK10 2NA
United Kingdom

The printed package leaflet of the medicinal product must state the name and address of the 

manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 

Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
AUTHORISATION 

 Periodic safety update reports 

The requirements for submission of periodic safety update reports for this medicinal product are set 

out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 

2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT

 Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the 

agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent 

updates of the RMP.

An updated RMP should be submitted:

 At the request of the European Medicines Agency;

 Whenever the risk management system is modified, especially as the result of new 
information being received that may lead to a significant change to the benefit/risk profile or 

as the result of an important (pharmacovigilance or risk minimisation) milestone being 

reached. 

 Obligation to conduct post-authorisation measures



52

The MAH shall complete, within the stated timeframe, the below measures:

Description Due date
PAES: In order to further confirm the efficacy of olaparib in patients with platinum-
sensitive relapsed BRCA mutated high grade serous ovarian cancer, the MAH should 
submit the results of study D0816C00002, a phase III randomised double-blind 
placebo-controlled multicentre study. 

The clinical study report should be submitted by: September
2020

PAES: In order to further define the efficacy of olaparib in patients with platinum-
sensitive relapsed somatic BRCA mutated high grade serous ovarian cancer, the MAH 
should conduct and submit the results of a phase IV, open label, single arm, non-
randomised, multicentre study in patients with relapsed platinum-sensitive ovarian 
cancer who are in complete or partial response following platinum-based 
chemotherapy and who carry loss of function germline or somatic BRCA mutation(s).

The clinical study report should be submitted by: December
2020

PAES: In order to further define the efficacy of olaparib in patients with platinum-
sensitive relapsed (PSR) non-germline BRCA mutated high grade ovarian cancer in the 
maintenance setting and investigate predictive biomarkers within this patient group, 
the MAH should submit the results of study D0816C00020 (OPINION), a phase IIIb 
single-arm, open-label, multicentre study of maintenance therapy in PSR non-germline 
BRCA mutated ovarian cancer patients who are in complete or partial response 
following platinum-based chemotherapy.

The clinical study report should be submitted by: June 2021

PAES: In order to further confirm the efficacy of olaparib as maintenance treatment 
after the first-line platinum-containing chemotherapy in patients with BRCA mutated 
high grade serous ovarian cancer, the MAH should submit the updated PFS2, updated 
OS and final OS results of the study D0818C00001 (SOLO1), a phase III randomised 
double-blind placebo-controlled multicentre study.

The clinical study report should be submitted by: December 
2023



53

ANNEX III

LABELLING AND PACKAGE LEAFLET



54

A. LABELLING



55

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 50 mg hard capsules
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each hard capsule contains 50 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule
448 capsules (4 bottles of 112 capsules)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza tablets unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2°C – 8°C).



56

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/14/959/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 50 mg 

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN



57

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

BOTTLE/LABEL

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 50 mg hard capsules
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each hard capsule contains 50 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule
112 capsules

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza tablets unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2°C – 8°C).



58

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/14/959/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA



59

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 100 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
56 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



60

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/14/959/002 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN



61

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 150 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 150 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
56 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



62

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/14/959/004 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN



63

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON MULTIPACK -including the blue box

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 100 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
Multipack: 112 (2 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



64

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER

EU/1/14/959/003 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC 
SN
NN



65

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON MULTIPACK -including the blue box

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 150 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 150 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
Multipack: 112 (2 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



66

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER

EU/1/14/959/005 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC 
SN 
NN 



67

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

INNER CARTON – with no blue box

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 100 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
56 film-coated tablets
Component of a multipack, not to be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



68

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER

EU/1/14/959/003 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA



69

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

INNER CARTON – with no blue box

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 150 mg film-coated tablets
olaparib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 150 mg of olaparib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
56 film-coated tablets
Component of a multipack, not to be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not switch to Lynparza capsules unless your doctor tells you

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.



70

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER

EU/1/14/959/005 

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

lynparza 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA



71

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 100 mg tablets
olaparib

2. NAME OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca 

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER



72

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Lynparza 150 mg tablets
olaparib

2. NAME OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca 

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER



73

B. PACKAGE LEAFLET



74

Package leaflet: Information for the patient

Lynparza 50 mg hard capsules
olaparib

Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you.

 Keep this leaflet. You may need to read it again. 
 If you have any further questions, ask your doctor, pharmacist or nurse.
 This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 
 If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible 

side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Lynparza is and what it is used for 
2. What you need to know before you take Lynparza
3. How to take Lynparza
4. Possible side effects 
5. How to store Lynparza
6. Contents of the pack and other information

1. What Lynparza is and what it is used for 

What Lynparza is and how it works

Lynparza contains the active substance olaparib. Olaparib is a type of cancer medicine called a PARP 
inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor). 

In patients with mutations (changes) in certain genes called BRCA (breast cancer gene), who are at risk 
of developing some forms of cancer, PARP inhibitors are able to trigger the death of cancer cells by 
blocking an enzyme that helps repair DNA.

What Lynparza is used for

Lynparza is used for the treatment of a type of ovarian cancer called “BRCA-mutated ovarian cancer”. 
It is used after the cancer has responded to previous treatment with standard platinum-based 
chemotherapy. A test is used to determine whether you have BRCA-mutated cancer.

2. What you need to know before you take Lynparza

Do not take Lynparza
 if you are allergic to olaparib or any of the other ingredients of this medicine (listed in section 6)
 if you are breast-feeding (see section 2 below for more information).

Do not take Lynparza if any of the above apply to you. If you are not sure, talk to your doctor, 
pharmacist or nurse before taking Lynparza. 

Warnings and precautions 
Talk to your doctor, pharmacist or nurse before or during treatment with Lynparza

 if you have low blood cell counts on testing. These may be low counts for red or white blood 
cells or low platelet counts. See section 4 for more information about these side effects, 



75

including the signs and symptoms you need to look out for (for example, fever or infection, 
bruising or bleeding). Rarely, these may be a sign of more serious problems with the bone 
marrow such as ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukaemia’ (AML). 

 if you experience any new or worsening symptoms of shortness of breath, coughing, or 
wheezing. A small number of patients treated with Lynparza reported inflammation of the lungs 
(pneumonitis). Pneumonitis is a serious condition that can often require hospital treatment.

If you think any of these may apply to you, talk to your doctor, pharmacist or nurse before or during 
treatment with Lynparza.

Tests and checks
Your doctor will check your blood before and during treatment with Lynparza. 

You will have a blood test
 before treatment
 every month for the first year of treatment
 at regular intervals decided by your doctor after the first year of treatment. 
If your blood count falls to a low level, you may need to have a blood transfusion (where you are 
given new blood or blood-based products from a donor).

Other medicines and Lynparza
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines. This includes medicines obtained without a prescription and herbal medicines. This is 
because Lynparza can affect the way some other medicines work. Also, some other medicines can 
affect the way Lynparza works.

Tell your doctor, pharmacist or nurse if you are taking or are planning to take any of the following 
medicines
 any other anticancer medicines
 a vaccine or a medicine that suppresses the immune system, as you may need to be closely 

monitored
 itraconazole, fluconazole - used for fungal infections
 telithromycin, clarithromycin, erythromycin - used for bacterial infections
 protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir, nevirapine, 

efavirenz - used for viral infections, including HIV
 rifampicin, rifapentine, rifabutin - used for bacterial infections, including tuberculosis (TB)
 phenytoin, carbamazepine, phenobarbital - used as a sedative or to treat fits (seizures) and 

epilepsy
 herbal remedies containing St John’s Wort (Hypericum perforatum) - used mainly for 

depression
 digoxin, diltiazem, furosemide, verapamil, valsartan – used to treat heart conditions or high 

blood pressure
 bosentan – used to treat pulmonary artery hypertension
 statins, for example simvastatin, pravastatin, rosuvastatin – used to lower blood cholesterol 

levels
 dabigatran – used to thin the blood
 glibenclamide, metformin, repaglinide – used to treat diabetes
 ergot alkaloids – used to treat migraines and headaches
 fentanyl – used to treat cancer pain 
 pimozide, quetiapine – used to treat mental health problems
 cisapride – used to treat stomach problems
 colchicine – used to treat gout
 cyclosporine, sirolimus, tacrolimus – used to suppress the immune system
 methotrexate – used to treat cancer, rheumatoid arthritis and psoriasis.



76

Tell your doctor, pharmacist or nurse if you are taking any of the above or any other medicines. The 
medicines listed here may not be the only ones that could affect Lynparza.

Lynparza with drink
Do not drink grapefruit juice while you are being treated with Lynparza. It can affect the way the 
medicine works. 

Contraception, pregnancy and breast-feeding 
 You should not take Lynparza if you are pregnant or might become pregnant. This is because it 

may harm an unborn baby.
 You should not become pregnant while taking this medicine. If you are having sex, you should

use two effective methods of contraception while taking this medicine and for 1 month after 
taking the last dose of Lynparza. It is not known whether Lynparza may affect the effectiveness 
of some hormonal contraceptives. Please tell your doctor if you are taking a hormonal 
contraceptive, as your doctor may recommend the addition of a non-hormonal contraceptive 
method. 

 You should have a pregnancy test before starting Lynparza, at regular times during treatment 
and 1 month after taking the last dose of Lynparza. If you become pregnant during this time, 
you must talk to your doctor straight away. 

 It is not known whether Lynparza passes into breast milk. Do not breast-feed if you are taking 
Lynparza and for 1 month after taking the last dose of Lynparza. If you are planning to 
breast-feed, tell your doctor.

Driving and using machines
Lynparza may influence your ability to drive and use machines. If you feel dizzy, weak or tired while 
taking Lynparza, do not drive or use tools or machines.

3. How to take Lynparza

Your doctor has prescribed Lynparza capsules for you. Please note Lynparza is also available as a 
100 mg and 150 mg tablet. 
 The doses of Lynparza capsules and tablets are not the same. 
 Taking the wrong dose or a tablet instead of a capsule could lead to Lynparza not working 

properly or to more side effects.
Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your 
doctor, pharmacist or nurse if you are not sure. 

How to take
 Take one dose (8 capsules) of Lynparza by mouth with water, once in the morning and once in 

the evening.
 Take Lynparza at least one hour after eating food. Do not eat preferably for up to 2 hours after 

taking Lynparza.

How much to take
 Your doctor will tell you how many capsules of Lynparza to take. It is important that you take 

the total recommended dose each day. Keep doing so for as long as your doctor, pharmacist or 
nurse tells you to.

 The usual recommended dose is 8 capsules (400 mg) taken by mouth twice a day (a total of 
16 capsules each day). 

Your doctor may prescribe a different dose if
 you have problems with your kidneys. You will be asked to take 6 capsules (300 mg) twice a 

day - a total of 12 capsules each day.
 you are taking certain medicines that may affect Lynparza (see section 2).



77

 you have certain side effects while you are taking Lynparza (see section 4). Your doctor may 
lower your dose or stop treatment, either for a short time or permanently.

If you take more Lynparza than you should
If you take more Lynparza than your normal dose, contact your doctor or nearest hospital straight 
away.

If you forget to take Lynparza
If you forget to take Lynparza, take your next normal dose at its scheduled time. Do not take a double 
dose (two doses at the same time) to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor straight away if you notice any of the following

Very common (may affect more than 1 in 10 people)
 feeling short of breath, feeling very tired, pale skin or fast heart beat - these may be symptoms of 

a decrease in the number of red blood cells (anaemia). 

Uncommon (may affect up to 1 in 100 people)
 allergic reactions (e.g. hives, difficulty breathing or swallowing, dizziness which are signs and 

symptoms of hypersensitivity reactions).

Other side effects include

Very common (may affect more than 1 in 10 people)
 feeling sick (nausea)
 being sick (vomiting)
 feeling tired or weak
 indigestion or heartburn (dyspepsia)
 pain in the stomach area under the ribs (upper abdominal pain)
 loss of appetite
 headache
 changes in taste of foods (dysgeusia)
 feeling dizzy
 cough
 shortness of breath
 diarrhoea – if it gets severe, tell your doctor straight away.

Very common side effects that may show up in blood tests
 decrease in the number of platelets in blood (thrombocytopenia) - you may notice the following 

symptoms:
o bruising or bleeding for longer than usual if you hurt yourself

 low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight 
infection and may be associated with fever.

Common (may affect up to 1 in 10 people)
 rash or itchy rash on swollen, reddened skin (dermatitis)
 sore mouth (stomatitis).

Common side effects that may show up in blood tests



78

 low white blood cell count (lymphopenia) which may decrease your ability to fight infection 
and may be associated with fever

 increase in blood creatinine - this test is used to check how your kidneys are working.

Uncommon side effects that may show up in blood tests
 increase in the size of red blood cells (not associated with any symptoms).

Your doctor will test your blood every month for the first year of treatment and at regular intervals 
after that. Your doctor will tell you if there are any changes in your blood test that might need 
treatment.

If you notice any side effects not listed in this leaflet, please contact your doctor straight away.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.

5. How to store Lynparza

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP. 
The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

Do not freeze. Throw away any Lynparza capsules that have been frozen.

If preferred, you can keep Lynparza capsules out of the refrigerator (below 30°C) for up to 3 months. 
After this period, throw away any capsules that have not been used. It is recommended that you record
the date when the capsules are removed from refrigerator and the date after which they should be
discarded.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Lynparza contains 
The active substance is olaparib. Each hard capsule contains 50 mg of olaparib.

The other ingredients (excipients) are
 Capsule content: lauroyl macrogol-32 glycerides. 
 Capsule shell: hypromellose, titanium dioxide (E171), gellan gum (E418), potassium acetate. 
 Printing ink: shellac, iron oxide black (E172).

What Lynparza looks like and contents of the pack

Lynparza is a white, opaque, hard capsule, marked with “OLAPARIB 50 mg” and the AstraZeneca 
logo in black ink. 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


79

Lynparza is provided in HDPE plastic bottles containing 112 hard capsules. One pack contains 
448 capsules (4 bottles of 112 capsules).

Marketing Authorisation Holder 

AstraZeneca AB
SE-151 85 Södertälje
Sweden

Manufacturer

AstraZeneca AB
Gärtunavägen
SE-151 85 Södertälje
Sweden

AstraZeneca UK Limited
Silk Road Business Park
Macclesfield, Cheshire, SK10 2NA
United Kingdom

For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:

België/Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 11

Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660550

България
АстраЗенека България ЕООД
Тел.: +359 24455000

Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
Tél/Tel: +32 2 370 48 11

Česká republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 111

Magyarország
AstraZeneca Kft.
Tel.: +36 1 883 6500

Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 62

Malta
Associated Drug Co. Ltd
Tel: +356 2277 8000

Deutschland
AstraZeneca GmbH
Tel: +49 41 03 7080

Nederland
AstraZeneca BV
Tel: +31 79 363 2222

Eesti
AstraZeneca 
Tel: +372 6549 600

Norge
AstraZeneca AS
Tlf: +47 21 00 64 00

Ελλάδα
AstraZeneca A.E.
Τηλ: +30 210 6871500

Österreich
AstraZeneca Österreich GmbH
Tel: +43 1 711 31 0

España
AstraZeneca Farmacéutica Spain, S.A.

Polska
AstraZeneca Pharma Poland Sp. z o.o.



80

Tel: +34 91 301 91 00 Tel.: +48 22 245 73 00

France
AstraZeneca
Tél: +33 1 41 29 40 00

Portugal
AstraZeneca Produtos Farmacêuticos, Lda.
Tel: +351 21 434 61 00

Hrvatska 
AstraZeneca d.o.o.
Tel: +385 1 4628 000

România
AstraZeneca Pharma SRL
Tel: +40 21 317 60 41

Ireland
AstraZeneca Pharmaceuticals (Ireland) DAC
Tel: +353 1609 7100

Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35 600

Ísland
Vistor hf.
Sími: +354 535 7000

Slovenská republika
AstraZeneca AB, o.z.
Tel: +421 2 5737 7777 

Italia
AstraZeneca S.p.A.
Tel: +39 02 9801 1

Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23 010

Κύπρος
Αλέκτωρ Φαρµακευτική Λτδ
Τηλ: +357 22490305

Sverige
AstraZeneca AB
Tel: +46 8 553 26 000

Latvija
SIA AstraZeneca Latvija
Tel: +371 67377100

United Kingdom
AstraZeneca UK Ltd
Tel: +44 1582 836 836

This leaflet was last revised in 

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu.

http://www.ema.europa.eu/


81

Package leaflet: Information for the patient

Lynparza 100 mg film-coated tablets
Lynparza 150 mg film-coated tablets

olaparib

Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you.
 Keep this leaflet. You may need to read it again. 
 If you have any further questions, ask your doctor, pharmacist or nurse.
 This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 
 If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible 

side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Lynparza is and what it is used for 
2. What you need to know before you take Lynparza
3. How to take Lynparza
4. Possible side effects 
5. How to store Lynparza
6. Contents of the pack and other information

1. What Lynparza is and what it is used for 

What Lynparza is and how it works

Lynparza contains the active substance olaparib. Olaparib is a type of cancer medicine called a PARP 
inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor).

PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. These specific 
cancer cells can be identified by:
 response to platinum chemotherapy, or
 looking for faulty DNA repair genes, such as BRCA (BReast CAncer) genes.

What Lynparza is used for

Lynparza is used for the treatment of

 a type of ovarian cancer (BRCA-mutated) that has responded to the first treatment with 
standard platinum-based chemotherapy.  

o A test is used to find out whether you have BRCA-mutated ovarian cancer.

 ovarian cancer that has come back (recurred). It can be used after the cancer has responded 
to previous treatment with standard platinum-based chemotherapy. 

 a certain type of breast cancer (BRCA-mutated, HER2-negative) which has spread beyond 
the original tumour. You should have received chemotherapy medicines either before or after 
your cancer has spread.  

o A test is used to find out whether you have BRCA-mutated breast cancer.

 a type of pancreatic cancer (BRCA-mutated) that has responded to the first treatment with 
standard platinum-based chemotherapy.  



82

o A test is used to find out whether you have BRCA-mutated pancreatic cancer.

2. What you need to know before you take Lynparza

Do not take Lynparza
 if you are allergic to olaparib or any of the other ingredients of this medicine (listed in section 6)
 if you are breast-feeding (see section 2 below for more information).

Do not take Lynparza if any of the above apply to you. If you are not sure, talk to your doctor, 
pharmacist or nurse before taking Lynparza.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before or during treatment with Lynparza

 if you have low blood cell counts on testing. These may be low counts for red or white blood 
cells, or low platelet counts. See section 4 for more information about these side effects, 
including the signs and symptoms you need to look out for (for example, fever or infection, 
bruising or bleeding). Rarely, these may be a sign of more serious problems with the bone 
marrow such as ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukaemia’ (AML).

 if you experience any new or worsening symptoms of shortness of breath, coughing or 
wheezing. A small number of patients treated with Lynparza reported inflammation of the lungs 
(pneumonitis). Pneumonitis is a serious condition that can often require hospital treatment.

If you think any of these may apply to you, talk to your doctor, pharmacist or nurse before or during 
treatment with Lynparza.

Tests and checks
Your doctor will check your blood before and during treatment with Lynparza. 

You will have a blood test
 before treatment
 every month for the first year of treatment
 at regular intervals decided by your doctor after the first year of treatment. 
If your blood count falls to a low level, you may need to have a blood transfusion (where you are 
given new blood or blood-based products from a donor).

Other medicines and Lynparza
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines. This includes medicines obtained without a prescription and herbal medicines. This is 
because Lynparza can affect the way some other medicines work. Also, some other medicines can 
affect the way Lynparza works.

Tell your doctor, pharmacist or nurse if you are taking or are planning to take any of the following 
medicines 
 any other anticancer medicines
 a vaccine or a medicine that suppresses the immune system, as you may need to be closely 

monitored
 itraconazole, fluconazole - used for fungal infections
 telithromycin, clarithromycin, erythromycin - used for bacterial infections
 protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir, nevirapine, 

efavirenz - used for viral infections, including HIV
 rifampicin, rifapentine, rifabutin - used for bacterial infections, including tuberculosis (TB)
 phenytoin, carbamazepine, phenobarbital - used as a sedative or to treat fits (seizures) and 

epilepsy



83

 herbal remedies containing St John’s Wort (Hypericum perforatum) -used mainly for depression
 digoxin, diltiazem, furosemide, verapamil, valsartan - used to treat heart conditions or high 

blood pressure
 bosentan - used to treat pulmonary artery hypertension
 statins, for example simvastatin, pravastatin, rosuvastatin - used to lower blood cholesterol 

levels
 dabigatran – used to thin the blood
 glibenclamide, metformin, repaglinide - used to treat diabetes
 ergot alkaloids - used to treat migraines and headaches
 fentanyl - used to treat cancer pain 
 pimozide, quetiapine - used to treat mental health problems
 cisapride - used to treat stomach problems
 colchicine – used to treat gout
 cyclosporine, sirolimus, tacrolimus - used to suppress the immune system
 methotrexate - used to treat cancer, rheumatoid arthritis and psoriasis.

Tell your doctor, pharmacist or nurse if you are taking any of the above or any other medicines. The 
medicines listed here may not be the only ones that could affect Lynparza.

Lynparza with drink
Do not drink grapefruit juice while you are being treated with Lynparza. It can affect the way the 
medicine works. 

Contraception, pregnancy and breast-feeding
Female patients
 You should not take Lynparza if you are pregnant or might become pregnant. This is because it 

may harm an unborn baby.
 You should not become pregnant while taking this medicine. If you are having sex, you should 

use two effective methods of contraception while taking this medicine and for 1 month after 
taking the last dose of Lynparza. It is not known whether Lynparza may affect the effectiveness 
of some hormonal contraceptives. Please tell your doctor if you are taking a hormonal 
contraceptive, as your doctor may recommend the addition of a non-hormonal contraceptive 
method.

 You should have a pregnancy test before starting Lynparza, at regular times during treatment 
and 1 month after taking the last dose of Lynparza. If you become pregnant during this time, 
you must talk to your doctor straight away. 

 It is not known whether Lynparza passes into breast milk. Do not breast-feed if you are taking 
Lynparza and for 1 month after taking the last dose of Lynparza. If you are planning to 
breast-feed, tell your doctor.

Male patients
 You must use a condom when having sex with a female partner, even if she is pregnant, while 

taking Lynparza and for 3 months after taking the last dose. It is not known whether Lynparza 
passes into semen.

 Your female partner must also use a suitable method of contraception. 
 You must not donate sperm while taking Lynparza and for 3 months after taking the last dose.

Driving and using machines
Lynparza may influence your ability to drive and use machines. If you feel dizzy, weak or tired while 
taking Lynparza, do not drive or use tools or machines.

Information on other ingredients in this medicine
This medicine contains less than 1 mmol sodium (23 mg) per 100 mg or 150 mg tablet, that is to say 
essentially “sodium-free”.

3. How to take Lynparza



84

Your doctor has prescribed Lynparza film-coated tablets for you. Please note Lynparza is also 
available as a 50 mg capsule. 
 The doses of Lynparza tablets and capsules are not the same. 
 Taking the wrong dose or a capsule instead of a tablet could lead to Lynparza not working 

properly or to more side effects.

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your 
doctor, pharmacist or nurse if you are not sure.

How to take
 Swallow Lynparza tablets whole, with or without food.
 Take Lynparza once in the morning and once in the evening.
 Do not chew, crush, dissolve or divide the tablets as this may affect how quickly the medicine 

gets into your body.

How much to take
 Your doctor will tell you how many tablets of Lynparza to take. It is important that you take the 

total recommended dose each day. Keep doing so for as long as your doctor, pharmacist or 
nurse tells you to.

 The usual recommended dose is 300 mg (2 x 150 mg tablets) twice a day - a total of 4 tablets 
each day.

Your doctor may prescribe a different dose if
 you have problems with your kidneys. You will be asked to take 200 mg (2 x 100 mg tablets) 

twice a day – a total of 4 tablets each day.
 you are taking certain medicines that may affect Lynparza (see section 2).
 you have certain side effects while you are taking Lynparza (see section 4). Your doctor may 

lower your dose or stop treatment, either for a short time or permanently.

If you take more Lynparza than you should
If you take more Lynparza than your normal dose, contact your doctor or the nearest hospital straight 
away.

If you forget to take Lynparza
If you forget to take Lynparza, take your next normal dose at its scheduled time. Do not take a double 
dose (two doses at the same time) to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. 

Tell your doctor straight away if you notice any of the following

Very common (may affect more than 1 in 10 people)
 feeling short of breath, feeling very tired, pale skin or fast heart beat – these may be symptoms 

of a decrease in the number of red blood cells (anaemia).

Uncommon (may affect up to 1 in 100 people)
 allergic reactions (e.g. hives, difficulty breathing or swallowing, dizziness which are signs and 

symptoms of hypersensitivity reactions).



85

Other side effects include

Very common (may affect more than 1 in 10 people)
 feeling sick (nausea)
 being sick (vomiting)
 feeling tired or weak
 indigestion or heartburn (dyspepsia)
 pain in the stomach area under the ribs (upper abdominal pain)
 loss of appetite
 headache
 changes in taste of foods (dysgeusia)
 feeling dizzy
 cough
 shortness of breath
 diarrhoea - if it gets severe, tell your doctor straight away.

Very common side effects that may show up in blood tests
 decrease in the number of platelets in blood (thrombocytopenia) - you may notice the following 

symptoms:
o bruising or bleeding for longer than usual if you hurt yourself

 low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight 
infection and may be associated with fever.

Common (may affect up to 1 in 10 people)
 rash or itchy rash on swollen, reddened skin (dermatitis)
 sore mouth (stomatitis).

Common side effects that may show up in blood tests
 low white blood cell count (lymphopenia) which may decrease your ability to fight infection 

and may be associated with fever
 increase in blood creatinine - this test is used to check how your kidneys are working.

Uncommon side effects that may show up in blood tests:
 increase in the size of red blood cells (not associated with any symptoms).

Your doctor will test your blood every month for the first year of treatment and at regular intervals 
after that. Your doctor will tell you if there are any changes in your blood test that might need 
treatment.

If you notice any side effects not listed in this leaflet, please contact your doctor straight away.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.

5. How to store Lynparza

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month.

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


86

This medicine does not require any special temperature storage conditions.

Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Lynparza contains
The active substance is olaparib.
 Each Lynparza 100 mg film-coated tablet contains 100 mg olaparib.
 Each Lynparza 150 mg film-coated tablet contains 150 mg olaparib. 

The other ingredients (excipients) are
 Tablet core: copovidone, silica colloidal anhydrous, mannitol, sodium stearyl fumarate.
 Tablet coating: hypromellose, macrogol 400, titanium dioxide (E171), iron oxide yellow 

(E172), iron oxide black (E172) (150 mg tablets only).

See section 2 “Information on other ingredients in this medicine”.

What Lynparza looks like and contents of the pack

Lynparza 100 mg tablets are yellow to dark yellow, oval, bi-convex, film-coated tablets, marked with 
“OP100” on one side and plain on the other. 

Lynparza 150 mg tablets are green to green/grey, oval, bi-convex, film-coated tablets, marked with 
“OP150” on one side and plain on the other. 

Lynparza is supplied in packs containing 56 film-coated tablets (7 blisters of 8 tablets each), or 
multipacks containing 112 (2 packs of 56) film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder 

AstraZeneca AB
SE-151 85 Södertälje
Sweden

Manufacturer

AstraZeneca AB
Gärtunavägen
SE-151 85 Södertälje
Sweden

AstraZeneca UK Limited
Silk Road Business Park
Macclesfield, Cheshire, SK10 2NA
United Kingdom



87

For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:

België/Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 11

Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660550

България
АстраЗенека България ЕООД
Тел.: +359 24455000

Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
Tél/Tel: +32 2 370 48 11

Česká republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 111

Magyarország
AstraZeneca Kft.
Tel.: +36 1 883 6500

Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 62

Malta
Associated Drug Co. Ltd
Tel: +356 2277 8000

Deutschland
AstraZeneca GmbH
Tel: +49 41 03 7080

Nederland
AstraZeneca BV
Tel: +31 79 363 2222

Eesti
AstraZeneca 
Tel: +372 6549 600

Norge
AstraZeneca AS
Tlf: +47 21 00 64 00

Ελλάδα
AstraZeneca A.E.
Τηλ: +30 210 6871500

Österreich
AstraZeneca Österreich GmbH
Tel: +43 1 711 31 0

España
AstraZeneca Farmacéutica Spain, S.A.
Tel: +34 91 301 91 00

Polska
AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 245 73 00

France
AstraZeneca
Tél: +33 1 41 29 40 00

Portugal
AstraZeneca Produtos Farmacêuticos, Lda.
Tel: +351 21 434 61 00

Hrvatska 
AstraZeneca d.o.o.
Tel: +385 1 4628 000

România
AstraZeneca Pharma SRL
Tel: +40 21 317 60 41

Ireland
AstraZeneca Pharmaceuticals (Ireland) DAC
Tel: +353 1609 7100

Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35 600

Ísland
Vistor hf.
Sími: +354 535 7000

Slovenská republika
AstraZeneca AB, o.z.
Tel: +421 2 5737 7777 

Italia
AstraZeneca S.p.A.
Tel: +39 02 9801 1

Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23 010

Κύπρος Sverige



88

Αλέκτωρ Φαρµακευτική Λτδ
Τηλ: +357 22490305

AstraZeneca AB
Tel: +46 8 553 26 000

Latvija
SIA AstraZeneca Latvija
Tel: +371 67377100

United Kingdom
AstraZeneca UK Ltd
Tel: +44 1582 836 836

This leaflet was last revised in 

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu.

http://www.ema.europa.eu/

	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING  AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND  EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET